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Constitutive androstane receptor (CAR) is a nuclear receptor with classical function of 
mediation the metabolism of xenobiotics. However, a novel function has been discovered for 
CAR as a regulator of energy metabolism. It has been shown that CAR interacts with 
peroxisome proliferator-activated receptor γ coactivator 1 α (PGC1α), which is involved in 
various pathways connected to energy metabolism. PGC1α contains a conserved LXXLL 
motif and an arginine/serine-rich domain, and there is evidence that both regions interact with 
CAR. 
 
The aim of this study was to study the interactions between these two proteins. Interactions 
were studied using full-length proteins in reporter gene assays and co-purification 
experiments were performed using the ligand binding domain of CAR and the LXXLL motif 
and RS domain of PGC1α. Reporter gene assay showed that PGC1α increases the activity of 
CAR by 5.7-fold. Co-purification showed that the RS domain of PGC1α seems to interact 
with CAR. However, the LXXLL motif, which is the conserved motif in coactivators 
important for the interaction with nuclear receptors, did not interact with CAR. However, this 
could be due to the low level of LXXLL expression in Escherichia coli (E.coli). The co-
purification was also performed using synthetized LXXLL motif with optimized codons for 
the expression in bacterial cells, but the results were inconclusive. The co-purified protein 
should be confirmed with mass spectrometry. In conclusion, the activity of CAR is increased 
by PGC1α and there seems to be interaction between CAR and the RS domain of PGC1α. The 
LXXLL motif should be expressed in larger quantities in order to further investigate the 
interaction with CAR. 
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ABBREVATIONS 
 
aa amino acid 
AF activation function 
AhR aryl hydrocarbon receptor 
Akt/PKB serine/threonine protein kinase/protein kinase B 
AMPK adenosine monophosphate-activated protein kinase 
AR androgen receptor 
BAT brown adipose tissue 
bp base pair 
CAR constitutive androstane receptor 
cAMP cyclic adenosine monophosphate 
CITCO 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4- 
 dichlorobenzyl)oxime 
CREB cAMP-responsive element binding protein 
CYP cytochrome P-450 monooxygenase 
DBD DNA-binding domain 
E.coli Escherichia coli 
ER estrogen receptor 
ERR estrogen-related receptor 
FOXO1 forkhead transcription factor 
FXR farnesoid X receptor 
GR glucocorticoid receptor 
Hat histidine affinity tag 
HAT histone acetyltransferase 
HNF4 hepatocyte nuclear factor 4 
LB Lennox L Broth Base 
LBD ligand-binding domain 
LXXLL leucine-X aa-X aa-leucine-leucine motif 
LXXLLsyn synthetic LXXLL motif 
MCF-7 human caucasian breast adenocarsinoma 
MR mineralcorticoid receptor 
NCoR nuclear receptor corepressor 
  
NR nuclear receptor 
OD600 optical density at 600 nm 
PB phenobarbital 
PBREM Phenobarbital-responsive enhancer module 
PCR polymerase chain reaction 
PCS protein cleavage site 
PEI polyethyleneimine 
PGC1 peroxisome proliferator-activated receptor gamma co-activator-1 
PKA cAMP-dependent protein kinase 
PPAR peroxisome proliferator-activated receptor 
PR progesterone receptor 
PRC PGC1 related coactivator 
PXR pregnane X receptor 
RAR retinoid acid receptor 
RBS ribosome binding site 
RE response element 
RIP140 receptor interaction protein 140 
RS arginine/serine rich domain 
RXR retinoid X receptor 
SB super broth 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHP small heterodimeric partner 
SIRT1 silent information regulator 2 homologue 1 
SMILE small heterodimer partner interacting leucine zipper protein 
SMRT silencing mediator of retinoid and thyroid hormone receptor 
SRC-1 steroid receptor coactivator-1 
T1DM type 1 diabetes mellitus 
T2D type 2 diabetes 
TCPOBOP 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene  
TH thyroid hormone 
TR thyroid receptor 
TRB-3 tribbles homologue 3 
VDR vitamin D receptor 
WAT white adipose tissue 
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1 INTRODUCTION 
 
Gene activation and repression are regulated with various factors, including nuclear receptors 
and coactivators. Active nuclear receptors bind to DNA and recruit other proteins of the 
transcriptional machinery for the gene activation. One nuclear receptor is constitutive 
andostane receptor (CAR), which classical function is to regulate the metabolism of 
xenobiotics, such as drugs and environmental contaminants (Honkakoski et al. 1998). Recent 
studies show that CAR is also connected to energy metabolism, for example the expression of 
CAR is induced by caloric restriction (Ding et al. 2006). In addition, CAR has been shown to 
down-regulate gluconeogenesis and lipogenesis by repressing factors inducing these processes 
(Gao et al. 2009, Dong et al. 2009). It has been shown that CAR is activated by peroxisome 
proliferator-activated receptor γ coactivator 1 α (PGC1α) (Shiraki et al. 2003). PGC1α is a 
protein regulating various energy pathways, such as induction of thermogenesis, 
mitochondrial biogenesis and gluconeogenesis. PGC1α is expressed abundantly in tissues 
with high energy consumption, such as brown adipose tissue, heart and skeletal muscle 
(Knutti et al. 2000). 
 
The research on metabolic pathways is under great pressure due to the growing health 
problems of obesity and the onset of metabolic diseases, such as type 2 diabetes (T2D). This 
has generated the investigation of novel therapeutical targets. Both CAR and PGC1α have 
been connected to energy metabolism and could be possible targets. It is important to study 
the interactions of the proteins in the various pathways of energy metabolism for the design of 
new drugs. 
 
There have been only few studies concerning the interactions of CAR and PGC1 using 
purified proteins. There is clear evidence that PGC1α coactivates CAR but the details of the 
interaction is still unclear. It has been published that the N-terminal LXXLL motif interacts 
with the ligand binding domain of CAR and also the C-terminal arginine/serine-rich (RS) 
domain is important for the activation (Shiraki et al. 2003). Further investigation is needed in 
order to specify the interaction regions in CAR and PGC1α complex. 
 
 
 9 
2 LITERATURE REVIEW 
 
2.1 Transcriptional regulation 
 
Humans have approximately 20 000 – 25 000 genes and it is important that the regulation of 
these genes is under strict control (International Human Genome Sequencing Consortium 
2004). The transcription is controlled by proteins including general transcription factors, co-
factors, histones and chromatin remodeling proteins (Vaquerizas et al. 2009).  
 
Efficient packaging of DNA is managed by wrapping 147 base pairs of DNA around eight 
histones forming a nucleosome and the DNA with proteins is referred to as chromatin. The 
tight association of DNA to histones represses the gene expression, because the binding sites 
for the coactivator complexes are inaccessible. Therefore the remodeling of the chromatin is 
an important step in gene activation. There are two classes of chromatin remodeling factors: 
ATP-dependent nucleosome remodeling complexes and factors containing histone 
acetyltransferase (HAT) activity (Glass & Rosenfeld 2000). ATP-dependent chromatin 
remodeling complexes, such as SNF2 protein family of ATPases, facilitate the exposure of 
DNA sequences from tight packaging to nucleosomes (Flaus & Owen-Hughes 2011). 
Histones are remodeled by post-translational modifications, such as acetylation, methylation, 
ubiquitination and phosphorylation. HATs acetylate the amino groups in the histone tails, 
which leads to opening of the tightly packed chromatin (Torok & Grant 2004). 
 
The transcriptional machinery is a protein complex, which binds to gene regions and starts the 
transcription from DNA to RNA (Thomas & Chiang 2006). The preinitiation complex in 
eukaryotes includes RNA polymerase II (polII) and six additional transcription factors 
(TFIIA-H). TFIID binds to a TATA sequence, called TATA box, located in the  promoter 
DNA and this event promotes the entry of other general transcription factors, such as TATA-
binding protein-associated factors (TAFs) and the mediator protein complex. The TATA box 
is part of the core promoter region, which also includes the initiator and a downstream 
promoter element, that forms a platform for the transcriptional factors to bind. 
 
The binding of the preinitiation complex is regulated by nuclear transcription factors 
including nuclear receptors (NRs) and other protein complexes regulating them. Upstream of 
the TATA box, there are proximal and distant enhancer regions, in which NRs and nuclear 
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factors can bind (Lemon & Tjian 2000). The factors binding to the enhancers can induce the 
gene transcription by recruiting coactivators with HAT activity and thus making chromatin 
accessible for preinitiaton complex, or by recruiting a kinase to phosphorylate the carboxy-
terminal domain of polII and stimulate elongation (Farnham 2009). 
 
2.2 Nuclear receptors 
 
NRs are proteins, which function as transcriptional factors in the nucleus. NRs are involved in 
biological processes, such as development, cell differentiation and organ physiology, by 
modulating gene expression (Mangelsdorf et al. 1995). NRs function by interacting with 
different proteins forming complexes that repress or activate the gene expression. Many, but 
not all, NRs are activated by ligand binding, which results in recruitment of other proteins.  
 
2.2.1 Classification of NRs 
 
The human NR superfamily comprises from 48 receptors and they can be divided into six 
classes according to evolutionary analysis (Gronemeyer et al. 2004, Laudet 1997). The 
division of NRs to subfamilies is shown in Table 1. The first subfamily consists of receptors 
such as thyroid hormone receptor (TR), retinoic acid receptor (RAR), peroxisome 
proliferator-activated receptor (PPAR), vitamin D receptor (VDR), farnesoid X receptor 
(FXR) and constitutive androstane receptor (CAR). The second subfamily includes retinoic X 
receptor (RXR), hepatocyte nuclear factor 4 (HNF4) and some orphan receptors. The third 
subfamily consists of estrogen receptor (ER), estrogen-related receptor (ERR), glucocorticoid 
receptor (GR), androgen receptor (AR) and progesterone receptor (PR). The fourth subfamily 
comprises NGF-induced clone B, which is an orphan receptor and the fifth and sixth 
subfamilies include steroidogenic factor 1/Fushi Tarazu factor 1 and germ cell nuclear factor, 
respectively. There is also a subfamily 0 comprising small heterodimeric partner (SHP) and 
dosage-sensitive sex reversal (Laudet 1997, Aranda et al. 2001). 
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Table 1. Classification of NRs to subfamilies (Aranda & Pascual 2001, Gronemeyer et al. 2004, Cotnoir-
White et al. 2010) 
Subfamily NRs Name Ligand 
I 
TR, 
RAR, , 
PPAR, , 
 
VDR 
 
PXR 
 
CAR 
 
LXR, 
FXR 
RevErb, 
ROR, , 
 
Thyroid hormone receptor 
Retinoic acid receptor 
Peroxisome proliferator -activated 
receptor 
Vitamin D receptor 
 
Pregnane X receptor 
 
Constitutive androstane receptor 
 
Liver X receptor 
Farnesoid X receptor 
Reverse ErbA 
Retinoic acid-related orphan 
receptor 
Thyroid hormone 
Retinoic acid 
Fatty acids and their 
metabolites 
1,25-dihydroxy vitamin D3, 
bile acids 
Xenobiotics, toxic 
endobiotics 
Xenobiotics, toxic 
endobiotics 
Oxysterols 
Bile acids 
Heme 
Cholesterol, cholesteryl 
sulphate, retinoic acid 
II 
RXR, , 
COUP-TF, 
 
EAR-2 
HNF4, 
TLX 
PNR 
 
TR2 
TR4 
Retinoid X receptor 
Chicken ovalbumin upstream 
prototer transcription factor 
V-erbA-related protein 2 
Hepatocyte nuclear factor 4 
Tailles-related receptor 
Photoreceptor-specific nuclear 
receptor 
Testis receptor 2 
Testis receptor 4 
Retinoic acid 
Fatty acids 
 
Orphan 
Fatty acids 
Orphan 
Orphan 
 
Orphan 
Orphan 
III 
GR 
AR 
PR 
ER, 
ERR, , 
MR 
Glucocorticoid receptor 
Androgen receptor 
Progesterone receptor 
Estrogen receptor 
Estrogen-related receptor 
Mineralocorticoid receptor 
Glucocorticoids 
Androgens 
Progestins 
Estradiol, tamoxifen 
DES, 4-OH-tamoxifen 
Aldosterone, spirolactone 
IV NGFI-B, ,  NGF-induced clone B Orphan 
V 
SF-1 
LRH-1 
Steroidogenic factor  
Liver receptor homologue 1 
Phospholipids 
Phospholipids 
VI GCNF Germ cell nuclear factor Orphan 
0 
SHP 
DAX-1 
Small heterodimeric partner 
Dosage-sensitive sex reversal 
Orphan 
Orphan 
 
There are different ways to classify NRs to groups. Another way is to classify them according 
to their ligand properties and affinities into three groups: endocrine receptors, xenobiotic 
receptors and orphan receptors (Xie & Evans 2001, Sladek 2010, Li et al. 2003). Endocrine 
receptors can be referred as steroid hormone receptors or classical receptors and they bind 
ligands with high affinity (Gronemeyer et al. 2004). For example, endocrine receptors GR, 
ER, PR and VDR bind endogenous compounds glucocorticoids, estrogen, progesterone and 
vitamin D, respectively. Xenobiotic receptors were the first orphan receptors, but when 
 12 
xenobiotic ligands were discovered, they were classified as environmental sensors (Sladek 
2010). Thus, they are sometimes referred as adopted orphan receptors. Xenobiotic receptors 
bind ligands with lower affinity and broader specificity than endocrine receptors. CAR and 
PXR are classified into this group and they bind xenobiotics, such as drugs and environmental 
chemicals. Orphan receptors are true orphans for which no natural ligands have been 
identified and may be activated via alternative pathways (Xie & Evans 2001). 
 
2.2.2 Conserved modular structure of NRs 
 
The NRs have a similar overall structure composed of various functional domains (Aranda et 
al. 2001). The domains can be divided into five functional: A/B, C, D, E and F (Figure 1). 
The A/B region is in the N-terminus of the receptor and it contains the transcriptional 
activation function (AF-1) domain. The AF-1 domain mediates the ligand-independent 
activation of the receptor. The DNA-binding domain (DBD) is referred as C region and it was 
one of the first domain structures that had been discovered (Wrange & Gustafsson 1978). The 
DBD includes two regions called “zinc finger” consisting of four cysteines linked to one 
bivalent zinc ion. The D region acts as a hinge between the DBD and ligand-binding domain 
(LBD) and increases the flexibility of the structure. Some receptors have an additional F 
region at the C-terminus of the receptor but the precise function of this part is still unknown. 
 
 
Figure 1. Schematic representation of the conserved NR structure. The A/B region contains the activation 
function domain 1 (AF-1). The E region contains the activation function domain 2 (AF-2), the ligand-
binding pocket and the dimerization interface. The DNA-binding domain and the additional dimerization 
interface are located in the C region. The function of F region is unclear. 
 
The LBD or E region positioned at the C-terminal part of the receptor has multiple functions 
in addition to the ligand-binding. It promotes dimerization of the receptors and the 
interactions with other protein partners. The NR LBD is comprised of 11-13 α helices and the 
three dimensional of the structural fold is well conserved for all NRs (Figure 2) (Wurtz et al. 
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1996). All the helices, except the very last one, form a ligand-binding pocket (domain) and 
the last helix (helix 12) that is part of the AF-2 acts as a lid for the LBD when the ligand is 
bound. The size of the binding pocket varies between NRs (Li et al. 2003). The helices 3, 4 
and 12 have an important function for the interactions with cofactor proteins.  
 
 
Figure 2. Crystal structure of the CAR LDB. There are twelve helices in the LBD and helices 3 and 12 are 
important for coactivator binding. Coactivator is shown in orange, helix 12 in red and the heterodimeric 
partner human RXRα in grey. Helix X is a short linker between helices 11 and 12. 
 
2.2.3 Binding of NRs to DNA 
 
NRs can function as monomers, homodimers or heterodimers when binding to the DNA 
(Gronemeyer et al. 2004, Aranda et al. 2001). Most the receptors in the subfamily 1 form 
heterodimers, however in the subfamily 2 and 3 monomers or homodimers are more common. 
RXR is a common heterodimerization partner for multiple receptors, including CAR, VDR 
and RAR (Lefebvre et al. 2010). The dimerization is crucial for high-affinity binding to the 
DNA. Both DBD and LBD structures have been shown to be involved in dimerization. The 
NRs bind to specific DNA sequences called response elements (RE), which have the 
consensus hexameric sequence RGKTCA (R = A or G, K = G or T) with three nucleotide 
spacing (Dunlop et al. 2004). REs are proximal or distal elements located around target genes 
and for dimeric NRs the two REs can be in different orientations called inverted repeats (IR), 
direct repeats (DR) or everted repeats (ER) and this characterizes the binding of NR dimers or 
monomers to DNA (Aranda & Pascual 2001, Frank et al. 2003, Helsen et al. 2012). 
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2.3 Xenobiotic NRs 
 
Xenobiotics and drugs are metabolized in the liver to prevent the accumulation of potentially 
toxic substances in the body. There are three known receptors regulating the metabolism: aryl 
hydrocarbon receptor (AhR), constitutive androstane receptors (CAR) and pregnane X 
receptor (PXR) (Moreau et al. 2007). Elimination of the xenobiotics includes detection, 
metabolism, transport and excretion of the xenobiotic molecules. AhR, CAR and PXR act as 
xenosensors and regulate all the elimination processes mentioned above. AhR recognizes 
environmental substances including halogenated aromatic hydrocarbons, aromatic amines and 
polycyclic aromatic hydrocarbons, which are abundant in cigarette smoke and smog 
(Hankinson 1995). AHR belongs to a group of transcription factors, which contains conserved 
basic helix-loop-helix motif (Fukunaga et al. 1995).  
 
Pregnane X receptor (PXR), referred as NR1I2 in the nomenclature system, was discovered in 
a screen of mouse liver library using expressed sequence tags (Kliewer et al. 1998). PXR is 
expressed abundantly in liver and small intestine and also weakly in kidney and stomach. 
PXR is activated by steroids, including pregnanes, such as pregnenolone-16-carbonitrile 
(PCN), and it was alternatively referred as steroid and xenobiotic receptor, SXR, when 
discovered (Kliewer et al. 1998, Blumberg et al. 1998). Other ligands discovered to activate 
PXR are 5-pregnane-3,20-dione, 17-OH-pregnenolone, RU486, cyproterone-accetate, 
clotrimazole, rifampicin and nifedipine (Quattrochi & Guzelian 2001). 
 
2.3.1 CAR 
 
Constitutive androstane receptor (CAR), also referred as NR1I3, is an adopted orphan NR, 
which is highly expressed in liver (Baes et al. 1994). CAR forms a heterodimer with RXR and 
was first discovered to bind to a retinoic acid response elements, which consists of hexameric 
DR sequences AGGTCA with five nucleotide spacing. CAR is constitutively active in the 
absence of a ligand. The activation occurs via helix 12 of the AF-2 motif, which mediates not 
only the ligand-dependent but also the ligand-independent transactivation of the receptor 
(Choi et al. 1997). The constitutive activity is based on the recruitment of transcriptional 
coactivators. The first ligands discovered for CAR were androstane metabolites, androstanol 
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and androstenol, but interestingly they act as inverse agonist and repress the activity of CAR 
(Forman et al. 1998). 
 
CAR has a close relation to PXR since they both mediate drug metabolism by activating the 
gene expression of CYP genes (Honkakoski et al. 1998, Xie et al. 2004). CAR activates the 
expression of CYP2B genes in response to phenobarbital (PB) treatment. PB triggers the 
translocation of CAR from the cytoplasma to the nucleus, where CAR forms a heterodimer 
with RXR (Zelko et al. 2000). The CAR-RXR heterodimer binds to phenobarbital-responsive 
enhancer module (PBREM), which is located upstream of the CYP2B genes. Moreover, the 
CAR-RXR heterodimer can bind to XREM/ER-6 promoter sequences and enhance the 
activity of CYP3A genes. 
 
In addition to PB, other ligands have been identified. Ligands may have different effects on 
CAR activity, for example agonists enhance and inverse agonists suppress the activity of 
CAR. The ligand recognition by CAR shows species-specific differences. The properties of 
some common ligands for human (hCAR) and mouse CAR (mCAR) are shown in Table 2. 
One of the ligands working as mCAR agonist is 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene 
(TCPOBOP) (Tzameli et al. 2000). It selectively activates mCAR but has no effect on hCAR 
and has been shown to bind to hPXR (Moore et al. 2000). Another agonist, 6-(4-
chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime 
(CITCO), is specific to hCAR (Maglich et al. 2003). In addition, ligands having an effect on 
CAR’s activity and regulation of CYP genes, are chlorpromazine, 16-androstenes, 
progesterone and estrogens (Zelko et al. 2000). Clotrimazole binds to hCAR repressesing its 
activation (Moore et al. 2000). 
 
Table 2. Common ligands binding to human and/or mouse CAR. 
Ligand human CAR mouse CAR 
Steroids: 
Androstenol Strong inhibition Weak inhibition 
Estradiol Inhibition Activation 
Xenobiotics: 
Phenobarbital Activation Activation 
TCPOBOP No effect Strong activation 
CITCO Activation No effect 
Clotrimazole Inhibition No effect 
Chlorpromazole No effect Activation 
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2.3.2 CAR as a metabolic regulator 
 
In addition to drug and steroid metabolism, novel functions for CAR have been presented. It 
has been proposed that CAR plays a role in energy homeostasis and metabolism (Maglich et 
al. 2004). During caloric restriction CAR has been shown to decrease the thyroid hormone 
(TH), thyroxine and triiodothyronine, levels, which are important regulators of basal 
metabolic rate and are key modulators in weight loss and energy homeostasis on mammals 
(Kim 2008). There have been implications that CAR has various roles in induction, repression 
and blocking the expression of hepatic genes after PB treatment (Ueda et al. 2002). CAR 
represses the gene expression of enzymes important for energy metabolism including fatty 
acid oxidation and gluconeogenesis. In addition, CAR knockout mice showed induced gene 
expression of genes, such as Cyp4a10 and Cyp4a14, which encode microsomal lipid 
peroxidases and thus stimulating the peroxidation. This indicates that blocking of lipid 
peroxisomes by CAR may protect from oxidative damage of lipids in liver. 
 
The mechanisms of CAR-mediated response to caloric restriction crosstalks via multiple 
pathways (Ding et al. 2006). Fasting stimulates a pathway for the activation of CAR target 
genes, including Cyp2b10, Sult2a1, Oatp2 and Ugta1 (Figure 3). These genes are involved 
not only in drug metabolism but also in metabolism, transport and excretion of THs and other 
metabolites, such as steroids and bile acids. Fasting triggers a response in the body, where the 
levels of glucagon and adrenaline are increased. This activates the production of cyclic 
adenosine monophosphate (cAMP), which is an important secondary messenger in various 
biological processes. The increased intracellular level of cAMP activates PGC1α expression 
via cAMP-dependent protein kinase (PKA) and cAMP-response element binding protein 
(CREB). PGC1α coactivates HNF4α, which induces the expression of CAR. Finally, CAR 
and PGC1α complex induce the expression of CAR target genes by binding to the PBREM in 
the proximity of CAR target genes.  
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Figure 3. CAR mediated pathway in response to caloric restriction. Caloric restriction elevates the 
glucagon level, which increases cAMP. This results in activation of PKA signaling and CREB, which 
increases the expression of PGC1α. PGC1 α binds to HNF4 α activating the expression of CAR and also 
binds directly to CAR. This activation of CAR increases the expression of genes regulating the xenobiotic 
metabolism, which also regulates the metabolism of THs, other steroids and bile acids (modified from 
Ding et al. 2006).  
 
It has been shown that CAR regulates the metabolism of serum triglycerides (Maglich et al. 
2009). When CAR is induced with TCPOBOP treatment, the triglyceride levels increased 
during high-fat diet compared to control group. In CAR knockout mice, the serum triglyceride 
levels are at the same level as in wild-type mice without TCPOBOP treatment. The 
mechanism of CAR regulating the metabolism of triglycerides has been attributed to negative 
regulation of PPARγ activity. PPARγ regulates the gene expression of enzymes involving 
hepatic β-oxidation, which is an important pathway in fatty acid metabolism (Desvergne et al. 
2006). 
 
There have been contradictions in the effects of CAR with regard to weight loss. Some studies 
have shown that CAR increases the resistance to weight loss by decreasing the TH levels and 
therefore it has negative effects on obesity (Maglich et al. 2004, Ding et al. 2006). However, 
Gao and colleagues (Gao et al. 2009) showed that CAR is beneficial to obesity by inhibiting 
lipogenesis, secretion of very low density lipoprotein (VLDL), export of triglycerides and 
gluconeogenesis. In addition, CAR increases the energy expenditure of BAT and peripheral 
fat mobilization. 
 
 
 
 18 
2.3.3 CAR and its connection to diabetes 
 
Contrary to the effects on the resistance to weight loss, CAR has been shown to have positive 
effects on T2D symptoms (Dong et al. 2009). Activation of CAR decreases the serum glucose 
levels, represses gluconeogenesis and improves hepatic glucose uptake and insulin sensitivity. 
These effects are mediated by repression of gluconeogenetic genes phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and by activation of glucose 
uptake genes for hexokinase and phophogluconate dehydrogenase (PGD). This pathway is 
mediated via CAR repressing the activity of forkhead transcription factor (FOXO1), which is 
an activator of PEPCK1 and G6Pase genes in the presence of TCPOBOP (Figure 4) (Kodama 
et al. 2004). The fact that CAR is activated by FOXO1 indicates that there is crosstalk 
between drug metabolism and energy metabolism. Insulin mediated signaling inactivates 
FOXO1 by exporting it from the nucleus to the cytoplasm and therefore downregulating CAR 
expression in the nucleus. 
 
Repression of gluconeogenesis is not only mediated via FOXO1 pathway but there are also 
indications that CAR inhibits HNF4α (Figure 4) (Miao et al. 2006). CAR represses the 
activation of HNF4α in two mechanisms. Firstly, CAR-RXR competes with HNF4α for 
binding to the DR1 motif in the promoters of CYP7A1, CYP8B1 and PEPCK genes thus 
inhibiting their gene expressions. Secondly, CAR competes with HNF4α by binding to 
common coactivators TIF-2 and PGC1α. 
 
 
Figure 4. CAR mediated repression of factors responsible for energy metabolism. Energy status signals 
activate the expression of CAR, which represses lipogenesis and gluconeogenesis. CAR represses FOXO1, 
HNF4α and CREB, which increase gluconeogenesis by activating G6Pase and PEPCK1 (modified from 
Kodama et al. 2004, Moreau et al. 2007, Gao & Wie 2010). 
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CAR inhibits the expression of lipogenic genes in liver, WAT, BAT and skeletal muscle after 
treatment with TCPOBOP inhibited in high-fat diet mice (Gao et al. 2009). Due to the lack of 
CAR expression in WAT and BAT, it seems that these metabolic pathways are secondary to 
CAR activation in other tissues. It has been shown in the same study that PGC1α is 
suppressed by TCPOBOP treatment in this animal model, which is consistent with the 
metabolic benefit of CAR, contradicting the previous findings (Maglich et al. 2004). 
 
CAR has been linked to the increased drug metabolism in type 1 diabetes mellitus (T1DM) 
(Dong et al. 2009). Cyp2B10, Cyp3A11 and Cyp2C29 gene expressions are elevated in T1DM 
mouse models and expressions of these genes is absent in CAR knockout mice. This indicates 
the importance of CAR in the elevated drug metabolism in untreated or poorly treated T1DM. 
The pathways for CAR’s induction in T1DM were shown to involve elevated hepatic bile 
acids and adenosine monophosphate-activated protein kinase (AMPK) levels. Furthermore, 
the expression of PGC1α was increased indicating its contribution to the activation of CAR in 
T1DM. 
 
2.4 Coregulators 
 
The regulation of target genes by NRs requires the recruitment of other nuclear proteins 
(Rosenfeld & Glass 2001). One group of such proteins are coregulators that are divided to 
coactivators and corepressors, and are able to promote or repress the function of NRs, 
respectively. Binding of a ligand regulates the activation or repression of NRs and this 
promotes the recruitment of either coactivator or corepressor complexes, respectively 
(Rosenfeld et al. 2006). 
 
Coregulators can be classified to five groups by their properties (Lemon & Tijan 2000). The 
first group consists of coactivators and corepressors, such as TAFs and TFIIA, which target 
the core transcriptional machinery and promoter recognition. Proteins in the second group 
regulate DNA-binding and interact with other coregulators and the transcriptional machinery. 
The third group consists of variable factors, which interact with RNA polymerase, other 
regulators and some of them have enzymatic activity. One example of a third class factor is 
the mediator, which is a multiprotein complex that interacts with RNA polymerase. The 
fourth group includes coregulators, which possess chromatin-modifying activities, such as 
acetyltransferases or deacetylases. The regulators can acetylate or deacetylate various targets, 
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for example histones, histone-related proteins, other activators and regulators and also the 
transcriptional machinery. The final group consists of ATP-dependent chromatin remodeling 
factors that utilize ATP in reactions, which modify the chromatin structure. 
 
2.4.1 Coactivators 
 
Coactivators can be divided into two groups, primary and secondary coactivators (Stallcup et 
al. 2003). Primary coactivators bind directly to NRs and recruit secondary coactivators and 
thus forming a transcriptional activation complex (Figure 5). The secondary coactivators act 
in ATP-dependent chromatin modeling complexes and have HAT activity. These coactivators 
can modify the chromatin structure by acetylation or methylation of histones or other proteins. 
The coactivation complex promotes the recruitment of RNA polymerase II complex by 
interacting with the components of the transcriptional machinery. 
 
 
Figure 5. Primary and secondary coactivators. Primary coactivator shown in red, bind to NRs in orange 
and recruit secondary coactivators, shown in light blue. Secondary coactivators can acetylate or methylate 
histones in the nucleosomes thus activating transcription by helping the binding of the RNA polymerase II 
complex to DNA. Secondary coactivators can also directly interact with the transcriptional machinery 
(modified from Stallcup et al. 2003). 
 
Coactivators have one or more special LXXLL (where L is leucine and X any amino acid) 
motif, which is also referred as NR box, and can interact with NRs (Heery et al. 1997). The 
amount of LXXLL motifs can vary and they can be located in any part of the coactivator 
protein. For instance, steroid receptor coactivator-1α (SRC-1α) has four LXXLL motifs, three 
located in the middle and one in the C-terminal part and both CREB-binding protein (CBP) 
and p300 have two in the N-terminal part. The LXXLL motif interacts with the helices 3, 4 
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and 12 all located in the LBD of NRs. The amino acid residues surrounding the core sequence 
of the LXXLL motifs are important for the binding affinity and specificity to NRs 
(MacInerney et al. 1998, Chang et al. 1999). The interaction between the LXXLL motif and 
NR LBD is mediated by hydrophobic interactions and a hydrogen bond between charged 
amino acid residues (Savkur & Burris 2004). A lysine residue in the helix 3 of NR LBD and a 
glutamic acid residue of helix 12 form the hydrogen bond with the LXXLL motif. 
 
Coactivators have various roles in gene activation process. They can be involved in tissue 
promoter-specific activation, chromatin remodeling, platform proteins/HAT activation 
functions or mediator-like complex (Figure 6) (Rosenfeld & Glass 2001). One example of 
tissue promoter-spesific coactivator is PPAR coactivator (PGC). Platform proteins function 
as interaction surface for other proteins to attach. They consist of the p160 family of NR 
coactivators, such as steroid receptor coactivator 1 (SRC-1)/nuclear receptor coactivator 1 
(NCOA1), transcriptional intermediary factor 2 (TIF2)/GRIP1 and p300/CBP co-integrator 
associated protein (p/CIP)/amplified in breast cancer 1 (A1B1)/activator of the TR and RAR 
(ACTR)/receptor associated coactivator 3 (RAC3)/TR activator molecule 1 (TRAM-1) 
(Torchia et al. 1999). The p160 family interacts with the NR LBD and with secondary 
coactivators p300/CBP and methyltransferases, such as coactivator associated arginine 
methyltransferase 1 (CARM1) and protein arginine methyltransferase (PRMT1) via the AD2 
domain (Chen et al. 1999, Koh et al. 2001). p300/CBP, CARM1, PRMT1 and p160 family 
have HAT activity and thus enhancing the transcription by modifying chromatin with 
acetylation of histones. SNF2 protein family of ATPases, including SWI/SNF and RSC, 
function as ATP-dependent chromatin remodeling regulators. ATPases hydrolyse ATP in 
reactions that are connected to modification of chromatin structure (Lemon & Tjian 2000). 
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Figure 6. Schematic presentation of coactivator functions. Platform proteins bind other coactivators, such 
as CARM-1, but they also possess NR activation functions. Tissue promoter-specific proteins interact with 
NRs. Coactivators, which possess histone acetylationtransferase activation function modify the DNA 
packing to histone proteins. DNA and histone complex is referred as nucleosome. Acetylation of histones 
activates the binding of transcription machinery to gene initiation sequence. In addition, platform 
proteins can activate factors in the transcription machinery (modified from Rosenfeld &Glass 2001). 
 
2.4.2 Corepressors 
 
The other group of coregulators consists of corepressors, which are thought to repress gene 
transcription. The first corepressors discovered include nuclear receptor corepressor (NCoR) 
and silencing mediator of retinoid and thyroid hormone receptor (SMRT) (Xu et al. 1999). 
Other coregulators are receptor interacting protein 140 (RIP140), Hairless, Alien, ligand-
dependent corepressor (LCoR) and small ubiquitous nuclear corepressor (SUN-CoR) (Lazar 
2003, Aranda & Pascual 2001). RIP140 suppresses the expression of genes involved in 
metabolism (Christian et al 2006). It has four autonomous repression domains, but also 
contain has nine copies of the LXXLL motif, which is characteristic for coactivators and 
important for interaction with NRs (Christian et al. 2004). 
 
The widely studied NCoR and SMRT have two important characteristics. First, they bind to 
NRs is ligand-independent and second, they contain autonomous, transferable repression 
domains (Lazar 2003). SMRT has two independent repressor domains (Nagy et al. 1997) and 
NCoR has three repressor domains (Heinzel et al. 1997). NCoR and SMRT contain similar 
sequences as LXXLL motif, also referred as the NR box, and copreressors interact with NRs 
by binding with these sequences, called corepressor/nuclear receptor (CoRNR) box (Hu & 
Lazar 1999). Both, NCoR and SMRT, function by forming a complex with mammalian Sin3 
orthologue A (mSin3A) and histone deacetylase 1 (HDAC1) (Heinzel et al. 1997, Nagy et al. 
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1997). These complexes bind to NR in the absence of a ligand and HDAC1 forces the 
chromatin to inactive state and thus repressing the gene expression. 
 
A novel corepressor, small heterodimer partner interacting leucine zipper protein (SMILE), 
has been identified as an inhibitor for ER, GR, CAR and HNF4α signaling (Xie et al. 2009). 
SMILE interacts with NR via the LBD and represses the activity of the NR by competing with 
coactivators, such as GRIP1 or PGC1α. 
 
2.5 PGC1 family of coactivators 
 
The PGC1 family of proteins consists of transcriptional coactivators, which recruits other 
transcriptional regulator proteins. The members of this have been shown to be involved in 
various metabolic pathways (Finck & Kelly 2006). The family has three subtypes: PGC1α, 
PGC1β and PGC1-related coactivator (PRC). Both PGC1α and PGC1β are found in tissues 
with high energy consumption and mitochondrial level, such as brown adipose tissue (BAT), 
skeletal muscle and heart. In addition, PGC1α is expressed in liver and kidney and lower 
levels in brain, lung and small intestine (Knutti et al. 2000). The biological function of PRC is 
less known. PGC1α was discovered in brown adipose tissue after cold-induction (Puigserver 
et al. 1998). 
 
2.5.1 Modular structure of PGC1α 
 
The N-terminus of PGC1α has a NR interaction motif, LKKLL (where L is leucine and K is 
lysine), at 144 to 148 amino acids (aa) (Knutti et al. 2000). There are also two other LXXLL 
(where X represents any amino acid) motifs in the N-terminus, LLAVL (88-92 aa) and 
LLKYL (210-214 aa) (Rha et al. 2009). The C-terminus of PGC1 contains two arginine-
serine (RS)-rich domains (566-599 and 621-631 aa) and a RNA-binding domain (677-753 aa) 
(Knutti et al 2000). The schematic structure of PGC1α is shown in Figure 7. 
 
 24 
 
Figure 7 Schematic structure of PGC1α. PGC1α contains activation domain in the N-terminus and RNA 
processing motifs in the C-terminus. The LXXLL motifs are located in the activation domain and they are 
important for theinteraction with NRs. The RS domains and RNA recognition motif (RRM) are 
contributing to the RNA-processing (modified from Puigserver & Spiegelman 2003). 
 
hPGC1 and hPGC1 have two conserved activation domains, AD1 and AD2, located in the 
N-terminal region (Sadana & Park 2007). There are five negatively charged aspartic and 
glutamic acid residues in these domains, and there is a glutamic acid residue at position 83, 
which is conserved between PGC1 and PGC1. These amino acids were shown to be 
important for the transcriptional activation.  
 
2.5.2 Interaction of PGC1α with NRs 
 
PGC1α was originally discovered as a PPAR binding protein (Puigserver et al. 1998). It was 
shown that the LXXLL motif in PGC1α and DNA binding domain in PPAR are the regions 
that function as interaction surfaces. In addition, the deletion of the RS domain in PGC1α 
decreased the interaction and therefore it is involved in binding to PPAR. More accurate 
information concerning the interaction of the LXXLL motif with PPAR was discovered 
when it was shown that the LKKLL at residues 144-148 is sufficient for the interaction and 
activation by PGC1α (Li et al. 2008). The Puigserver group (Puigserver et al. 1998) also 
studied interactions with other NRs and TR, RARα and ERα bind to PGC1α. TR interacts 
with PGC1 in a ligand –independent manner, but ligand increases the binding by 2- to 3-fold. 
The binding of RARα and ERα to PGC1 seems to be ligand-dependent. More interactions 
between NRs and PGC1α were discovered when Knutti and coworkers (Knutti et al. 2000) 
investigated the activation of ER, AR, MR and GR by PGC1α in response to hormone 
addition. PGC1α enhanced the hormone-dependent transcription in ER, MR and GR and 
weakly in AR. Also ERRα was discovered to interact with PGC1α in heart tissue (Huss et al. 
2002). The ERRα binding to PGC1α differs from other receptors. ERRα binds via LLKYL 
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motif at position 210-214 aa in PGC1α and other receptors bind to LKKLL motif at 144-148 
aa.  
 
Despite the primary interaction of one LXXLL motif, the other two motifs can have an 
intensifying effect to the activation and also the surrounding amino acids affect the binding 
properties (Rha et al. 2009). The LLAVL motif of PGC1 is surrounded by alanine and 
asparagine in the amino acids positions two (-2) and one (-1) prior to the first leucine, the 
LKKLL motif is surrounded by serine at position -2 and leucine at position -1 and the 
LLKYL is surrounded by serine at position -2 and glutamic acid at position -1 (Figure 8). 
Serine and asparagine have polar, uncharged side chains, alanine and leucine have 
hydrophobic side chains and glutamic acid has a negatively charged side chain. This could 
affect the binding properties of different LXXLL motifs to NRs. 
 
 
Figure 8. Amino acids surrounding the LXXLL motifs in PGC1. Three LXXLL motifs are indicated in 
red. Amino acid position from the first leucine in the LXXLL motif is numbered as 1, amino acids prior to 
the LXXLL motif are numbered as -1 and -2 and amino acids after the LXXLL motif are numbered as +1 
and +2. 
 
PGC1α as well as other proteins is part of the large signaling network regulating various 
pathways and processes in the cellular context. Some of the known and predicted interactions 
between PGC1 and other protein partners using the STRING 9.0 protein interaction database 
(http://string-db.org/) are shown in Figure 8. PGC1 is activated by SIRT1 and insulin, 
however there is evidence that insulin also inhibits PGC1. Inhibition of PGC1 is mediated 
by FOXO1, which is inhibited by insulin. PGC1 activates EER and UCP1, which is also 
activated by PPAR. The evidence shows that PGC1 binds with FOXO1, ERR, PPAR, 
SIRT1 and CDK7. 
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Figure 9. Interactions of PGC1 with NRs and other factors. Blue lines represent binding between the two 
proteins, green arrows represent activation, red lines represents inhibition, pink lines represent post-
translational modifications, yellow lines represent expression and grey lines represent confidence of 
associations. SIRT = sirtuin 1, PPARG = peroxisome proliferators-activated receptor γ, FOXO1 = 
forkhead box O1, INS = insulin, ESRRA = estrogen-related receptor α, ESRRG = estrogen-related 
receptor γ, CDK7 = cyclin-dependent kinase 7, MAPK14 = mitogen-activated protein kinase 14, NRF1 = 
nuclear respiratory factor 1, UPC1 = uncoupling protein 1. Graph collected from STRING 9.0 online 
database for protein interactions (http://string-db.org/). 
 
It has been shown that PGC1α regulates the metabolic pathways in the liver by binding to 
PXR and HNF4 (Bhalla et al. 2004, Jover et al. 2009). PXR suppresses HNF4α signaling of 
cytochrome p450 (CYP) genes involving bile acid synthesis by competing for the binding of 
PGC1α.  
 
 Energy homeostasis mediated by PGC1
 
When first discovered, PGC1α was shown to regulate the expression of uncoupling protein 1 
(UCP1) (Puigserver et al. 1998). UCPs have an important role in thermogenesis and it is 
expressed in brown adipocytes and it functions in helping the oxidation processes to convert 
ADP to ATP in the inner mitochondria membrane (Flier & Lowell 1997). A recent study 
showed that PGC1α increases the expression of a membrane-bound protein, which is 
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modified into a hormone called irisin (Boström et al. 2012). Irisin stimulates the UCP1 gene 
expression and brown-fat-like development. Irisin is increased with exercise and moreover, it 
increases the energy expenditure. Moreover, it has been shown that PGC1α activates 
mitochondrial biogenesis in muscle cells, BAT and heart (Wu et al. 1999, Kelly & Scarpulla 
2004, Lehman et al. 2000). Muscle cells, adipocytes and heart tissue all have different levels 
of coupled and uncoupled mitochondrial respiration and the tissue-specificity is achieved via 
PGC1α. The pathway of biogenesis is mediated by transcriptional factors called nuclear 
respiratory factors (NRFs). Environmental stimuli, such as cold and high-calorie diet, release 
norepinephrine, activates -adrenergic receptors in the cell surface. This results in an increase 
of cAMP in the cytoplasm and leads to the induction of PGC1A gene expression. PGC1α 
induces the expression of NRFs and functions as a coactivator of NRF-1 activating the 
expression of genes encoding subunits of mitochondrial respiratory chain and mitochondrial 
transcription factor A. 
 
PGC1 is connected to mitochondrial respiratory processes by regulating reactive oxygen 
species (ROS), which are produced in the electron transport chain (St-Pierre et al. 2006). 
PGC1 is important to the oxidative stress defense system by inducing ROS-detoxifying 
enzymes, such as glutathione peroxidase, catalase and superoxide dismutase. This has notable 
results in the protection of neuronal cells, which are sensitive to the oxidative stress. 
 
Moreover, both PGC1 and PGC1 are important for mitochondrial biogenesis in insulin 
resistant mouse heart (Mitra et al. 2012). Loss-of-function studies showed that mice lacking 
PGC1 have decreased respiratory function and altered mitochondrial gene expression, which 
are induced by high fat diet in wild-type mice. Therefore lipid metabolism and mitochondrial 
dysfunction have important roles in diabetic heart failure. However, it has been also shown 
that the effects of PGC1α for mitochondrial biogenesis are restricted in insulin resistance, 
glucose intolerance or early stages of diabetes and in the later stages of diabetes PGC1 
expression is declined. 
 
In addition to tissues with high-energy consumption, PGC1α is expressed in the liver and it is 
induced during fasting or caloric restriction (Yoon et al. 2001). cAMP and glucocorticoids 
levels are elevated in the liver by fasting and it has been showed that these molecules activate 
the gene expression of PGC1α. Moreover, PGC1α increases the synthesis of glucose by 
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stimulating the expression of gluconeogenic enzymes, such as PEPCK and G6pase. In 
addition, it has been shown that PGC1α furthers insulin resistance in the liver (Koo et al. 
2004). PGC1 function with PPARα and activates mammalian tribbles homologue 3 (TRB-3), 
an inhibitor of the serine-threonine kinase/protein kinase B (Akt/PKB). Akt/PKB is part of 
insulin signaling pathway, which decreases the glucose output in the liver. TRB-3 is induced 
during fasting, in result of induction of PGC1 and PPARα. Tissue-specific functions of 
PGC1α are shown in Figure 10. 
 
 
Figure 10. PGC1α and its functions in the human body. PGC1α has tissue-specific functions and it is 
expressed in brown adipose tissue (BAT), liver, heart tissue and skeletal muscle. 
 
Bile acids are important regulators of cholesterol metabolism in the liver and their 
homeostasis is controlled by negative feedback through a NR, SHP (Eloranta & Kullak-
Ublick 2004). Bile acids are also shown to act as ligands for various NRs. Bhalla and 
colleagues (Bhalla et al. 2004) showed that binding of PXR to PGC1α represses bile acid 
synthesis in the liver. However, it has been discovered that bile acids inhibit PGC1α 
expression via SHP (Yamagata et al. 2007). Bile acids bind to FXR and this promotes the 
expression of SHP, which then interacts with FOXO1 and the complex binds into the 
promoter of PGC1α gene repressing the expression. 
 
PGC1 regulates triglyceride metabolism by activating FXR (Zhang et al. 2004). The mRNA 
transcription of PGC1 is increased during fasting and it increases the FXR transcription by 
coactivating PPAR and HNF4. PGC1-PPAR and PGC1-HNF4 complexes bind to 
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DR-1 element located in the FXR promoter region. Moreover, PGC1 binds directly to FXR 
to activate the FXR target genes that up-regulates the triglyceride clearance and down-
regulates triglyceride synthesis and leading to the activation of the fatty acid -oxidation. 
 
Due to the positive effects of PGC1α, there have been attempts to increase the levels of 
PGC1α. Exercise has been shown to elevate PGC1α levels (Franks & Loos 2006). In addition, 
food substances can induce PGC1α expression. Resveratrol, a polyphenolic compound found 
in the skin of the grapes and thus in red wine, was discovered to increase the activity of 
PGC1α (Lagouge et al. 2006). Resveratrol can induce the gene expression of PGC1α and 
moreover, regulate the post-translational modifications, for example acetylation. In this case, 
resveratrol indirectly activates silent information regulator 2 homologue 1 (also called sirtuin 
1, SIRT1), which then deacetylates and hence activates PGC1α. Sirtuins are proteins, which 
possess NAD
+
-dependent deacetylase and/or ADP-ribosyltransferase activities, and they have 
been connected to aging and energy metabolism (Li & Kazgan 2011). SIRT1 functions with 
PGC1α in liver and in adipose tissue. 
 
 Interactions between CAR and PGC1
 
There have been only a few studies done concerning the interactions between CAR and PCG-
1. These interactions have been studied using reporter gene analysis. It has been showed that 
CAR competes with HNF4α for binding to PGC1, which results in repression of the HNF4α 
target genes (Miao et al. 2006). Interactions between CAR and PGC1 were shown in a 
study, in which corepressor SMILE competes with PGC1 and this decreases the activation 
of CAR (Xie et al. 2009). Moreover, SMILE declines the expression of CAR target gene 
CYP2B6. 
 
The details of the interaction between CAR and PGC1 have been described by Shiraki and 
co-workers (Shiraki et al. 2003). They have published that CAR is activated by PCG-1 in a 
ligand-independed manner and have showed that the RS domain of PGC1 targets CAR to 
nuclear speckles but both regions, LXXLL and RS, are interacting with CAR. Deletions in 
PGC1 has showed that the removal of the LXXLL motif decreases CAR’s activity but does 
not abolish it and the removal of both RS and RRM domains also decreases its activity. Thus 
both regions, LXXLL and RS, are important for the activation of CAR. A schematic 
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representation of the target gene activation by interaction of PGC1 and CAR is shown in 
Figure 11. 
 
 
Figure 11. Gene activation by PGC1 and CAR interaction. PGC1 interacts with CAR and the CAR-
RXR heterodimer complex binds to the response element (RE) in the promoter DNA of the target gene. 
PGC1 recruits other coactivators, which activate the transcriptional machinery to initiate the expression 
of the target gene (modified from Finck & Kelly 2006). 
 
2.7 Metabolic diseases 
 
Metabolic diseases including obesity and cardiovascular disease related factors, such as high 
blood pressure, high levels of tricylglycerols and inflammation are increasing in the western 
population (Guarente 2006). These physiological symptoms are referred as metabolic 
syndrome. Metabolic syndrome is also connected to dysregulation of glucose homeostasis, 
which can lead to T2D.  
 
Obesity is a global health risk factor and in the year 2005 there were approximately 940 
million overweight and 400 million obese adults in the world (Kelly et al. 2008). Overweight 
and obesity are defined as body mass index 25-29.9 kg/m
2
 and  31 kg/m2, respectively. It has 
been estimated that in the year 2030, there will be 1.35 billion overweight and 573 million 
obese adults. This fact has outstanding effect on the health of the world’s population and has 
economic aspects due to other health issues it precedes, such as cardiovascular disease, 
cancer, diabetes and other associated complications.  
 
There are two types of diabetes mellitus. T1DM is known as insulin-dependent diabetes 
mellitus and it is an autoimmune disease and usually onsets at an early age (Fowler 2010). 
The second type is T2D, which is non-insulin-dependent and is connected to metabolic 
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dysfunction. T2D is caused by combination of insulin resistance, β-cell dysfunction and 
increased hepatic glucose production. Insulin resistance is associated with obesity and may be 
one of the reasons why T2D is common in obese individuals. However, not all obese 
individuals develop T2D. The crucial factor is β-cell dysfunction, which leads to decreased 
insulin release (Kahn et al. 2006). This affects the glucose regulation by increasing hepatic 
glucose production and reducing glucose uptake in insulin-sensitive tissues. Despite the 
decrease of insulin release in dysfunctional β-cells, the insulin resistance is compensated with 
enhanced β-cell mass, which leads to hyperinsulinemia (Polonsky 2000).  
 
Due to the extent public health related and economic effects, there is continuous research in 
finding therapeutical targets for obesity, metabolic syndrome and T2D. One investigated 
approach is targeting the transcriptional regulation complexes involved in the gene expression 
of the mediators in the metabolic pathways. 
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3 THE AIM OF THE WORK 
 
The aim of this practical part was to investigate the interactions of different regions of 
hPGC1 and hCAR-LBD. The work also includes the preparation of the tools necessary for 
the experiments. The aims can be summarized into the following points: 
1. Preparation of the co-expression vectors containing the recombinant hCAR-LBD and 
hPGC1-LXXLL, hPGC1-RS and synthetic hPGC1-LXXLL domains. 
2. Full optimization of the constructs using various E.coli bacterial host strains. 
3. Characterize the interaction between hCAR-LBD and hPGC1 domains using co-
purification. 
4. Study the activation of full-length CAR by full-length hPGC1 using reporter gene 
assay in mammalian cellular models. 
 33 
4 MATERIALS AND METHODS 
 
4.1 Reagents and media 
 
Table 3. List of chemicals. 
Name Company 
Carbenicillin Carbenicillin DIRECT, UK 
Chloramphenicol Sigma-Aldrich Co. LLC., St. Louis, USA 
Isopropyl-β-D-1-
thiogalactopyranoside (IPTG) 
Fermentas, Thermo Fisher Scientific Inc., 
Waltham, USA 
L-rhamnose monohydrate Carbosynth Limited, Berkshire, UK 
 
Table 4. List of bacterial growth media. 
Name Content Company 
Lennox L Broth Base (LB) 1 % peptone 
0.5 % yeast extract 
0.5 % NaCl 
BD, Franklin Lakes, USA 
BD, Franklin Lakes, USA 
Sigma-Aldrich Co. LLC., St. Louis, 
USA 
Super Broth (SB) 3.2 % tryptone 
2 % yeast extract 
0.5 % NaCl 
BD, Franklin Lakes, USA 
BD, Franklin Lakes, USA 
Sigma-Aldrich Co. LLC., St. Louis, 
USA 
N-Z-amine 1 % N-Z-amine A
®
 from bovine 
milk 
0.5 % yeast extract 
Sigma-Aldrich Co. LLC., St. Louis, 
USA  
BD, Franklin Lakes, USA 
 
Table 5. List of E. coli strains used for cloning and expression. 
Strain Usage Company 
XL-10 DNA amplification Stratagene, Agilent Technologies, Inc., 
Santa Clara, USA 
BL21(DE3) Protein expression Novagen EMD Millipore, Billerica, 
USA 
BL21-Gold (DE3)  DNA amplification and protein 
expression 
Stratagene, Agilent Technologies, Inc., 
Santa Clara, USA 
BL21(DE3) pRARE Protein production Novagen EMD Millipore, Billerica, 
USA 
Origami B (DE3) Protein production Novagen EMD Millipore, Billerica, 
USA 
 34 
Table 6. List of mammalian cell lines. 
Name Abbreviation Source Recommended 
medium 
Human hepatocellular carcinoma C3A ATCC, LGC 
Standards AB, 
Boras, Sweden 
ATCC-formulated 
Eagle's minimum 
essential medium, 10 
% fetal bovine serum 
Human caucasian breast 
adenocarcinoma 
MCF-7 ATCC, LGC 
Standards AB, 
Boras, Sweden 
ATCC-formulated 
Eagle's minimum 
essential medium, 
0.01 mg/ml bovine 
insulin, 10 % fetal 
bovine serum 
 
Table 7. List of media for mammalian cells 
Name Content Company 
Sub-culturing medium Dulbecco’s Modified Eagle 
Medium with phenol red, 10 
% fetal bovine serum, 1% L-
glutamine, 1 % penicillin-
streptomycin 
Gibco®, Life Technologies 
Corporation, Carlsbad, USA 
Sub-culturing medium before 
transfection 
Phenol red-free Dulbecco’s 
Modified Eagle Medium, 10 
% fetal bovine serum, 1% L-
glutamine, 1 % penicillin-
streptomycin 
Gibco®, Life Technologies 
Corporation, Carlsbad, USA 
Transfection medium Phenol red-free Dulbecco’s 
Modified Eagle Medium, 1% 
L-glutamine, 1 % penicillin-
streptomycin 
Gibco®, Life Technologies 
Corporation, Carlsbad, USA 
Ligand medium Phenol red-free Dulbecco’s 
Modified Eagle Medium, 5 % 
lipid-free serum, 1% L-
glutamine, 1 % penicillin-
streptomycin 
Gibco®, Life Technologies 
Corporation, Carlsbad, USA 
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4.2 Preparation of RbCl2 competent cells 
 
Competent E. coli BL21 cells were prepared using Rubidium method. Cells were inoculated 
from a glycerol stock and grown in 5 ml LB medium overnight at 37 C with 200 rpm 
shaking. Pre-culture was transferred to 250 ml LB and grown at 37 C with 200 rpm shaking 
for 1 h 50 min, when optical density at 600 nm (OD600) was measured with spectrophotometer 
(Varian Cary 50 UV/Vis spectrophotometer, Agilent, Santa Clara, USA). The cultivation was 
continued until OD600 reached 0.4. Then the culture was collected using 50 ml falcons and 
incubated for 15 min on ice. Cells were harvested by centrifugation at 2500 rpm for 15 min at 
4 C. Pellets were resuspended in 10 ml of transformation buffer 1 (TFB1: 10 mM MES, 100 
mM RbCl, 10 mM CaCl2  2 H2O, 50 mM MnCl2  2 H2O, pH 5.8), then split into two 50 ml 
falcons and the volume was increased to 40 ml with TFB1 in both falcons. Resuspended 
mixtures were incubated on ice for 15 min and centrifuged at 2500 rpm for 15 min at 4 C. 
Supernatants were discarded, the pellets were resuspended in transformation buffer 2 (TFB2: 
10 mM MOPS, 10 mM RbCl, 75 mM CaCl2  2 H2O, 15 % glycerol, pH 6.5) and incubated 
on ice for 15 min. The suspension of cells was aliquoted in microcentrifuge tubes, flash frozen 
in liquid nitrogen and stored at – 85 C until further use. 
 
4.3 Comparison of human and mouse PGC1  homology using BLAST 
 
Comparisons of nucleotide and amino acid sequences were performed in order to clarify the 
similarity between human and mouse PGC1. Nucleotide sequences were acquired from 
National Center for Biotechnology Information (NCBI) Nucleotide database 
(http://www.ncbi.nlm.nih.gov/nuccore) and nucleotide sequences were translated to amino 
acid sequences using a translate tool at Bioinformatics Resource Portal called ExPASy, at 
Swiss Institute of Bioinformatics (SIB) web site (http://web.expasy.org/translate/). The 
comparison between human and mouse PGC1 was performed using on-line Basic local 
alignment search tool (BLAST) at NCBI web site. Alignment was performed for both, 
nucleotide and amino acid, sequences using nucleotide blast and protein blast, respectively. 
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4.4 Molecular cloning of the recombinant protein constructs 
 
hCAR-LBD and hPGC1α-motifs/domains were cloned into a co-expression vector , 
pCoAT7H3F, containing a histidine affinity tag HAT (Takara Bio Europe/Clontech, Saint-
Germain-en-Laye, France) for the first protein coding gene and three copies of a synthetic 
FLAG protein tag (Sigma-Aldrich Co. LLC., St. Louis, USA) for the second gene. The vector 
contains ampicillin resistance, T7 promoter and terminator, lac operator (lacO), TEV (first 
gene) and 3C protein (second gene) cleavage sites (PCS), ribosome binding sites (RBS) and 
gene for lac repressor protein (lacI). T7 promoter and lacO are located in the 5’ promoter of 
both cloned protein genes. PCS are located after the affinity tags in order to facilitate removal 
of the tags if necessary. Table 8 summarizes the classical cloning of the inserts into co-
expression vector. In addition, a synthetized LXXLL domain (LXXLLsyn) with bacterial 
codon optimization was cloned into the pCoAT7H3F. LXXLLsyn domain was created for 
better expression of the recombinant protein in E. coli due to the bacterial codon optimization 
but its size is smaller compared to the LXXLL motif created from the wild-type full-length 
PGC1α. The maps of the constructed plasmids are shown in the appendix A. 
 
Table 8. Constructs prepared for recombinant protein expression and co-expression. 
Construct # 
Insert 
Vector Hat-hCAR 3xFLAG-hPGC1α 
Domain REs Domain REs 
1 LBD BamHI/NdeI   pCoAT7H3F 
2 LBD BamHI/NdeI FL 
BamHI/NcoI 
& NcoI 
pCoAT7H3F 
3 LBD BamHI/NdeI LXXLL NcoI pCoAT7H3F 
4 LBD BamHI/NdeI RS BamHI/NcoI pCoAT7H3F 
5 LBD BamHI/NdeI 
synthetic 
LXXLL 
BamHI/NcoI pCoAT7H3F 
6 - - FL 
BamHI/NcoI 
& NcoI 
pCoAT7H3F 
7 - - LXXLL NcoI pCoAT7H3F 
8 - - RS BamHI/NcoI pCoAT7H3F 
9 - - 
synthetic 
LXXLL 
BamHI/NcoI pCoAT7H3F 
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The full-length hPGC1α was amplified with polymerase chain reaction (PCR) with Phusion 
polymerase (Finnzymes, Thermo Fisher Scientific Inc., Waltham, USA) from cDNA 
template. PCR conditions are shown in Table 9 and the primers used are shown in Table 10. 
The PCR product was purified using PCR purification kit (Qiagen, Hilden, Germany). The 
purified PCR product was digested with NcoI alone or NcoI/BamHI in order to create 
different hPGC1α domain fragments such as hPGC1α-LXXLL was created with NcoI and 
hPGC1α-RS with NcoI/BamHI. The inserts were ligated into pCoAT7H3F after the 3xFLAG 
site. The ligation of the NcoI-cut LXXLL insert into pCoAT7H3F-hPGC1α-RS construct 
created the full-length hPGCa. hCAR-LBD was digested from pET15b-hCAR103-348 construct 
with NdeI/BamHI and ligated into the empty pCoAT7H3F after the HAT site and also into the 
previously created pCoAT7H3F-hPGC1α constructs. 
 
Table 9. PCR mixture for the amplification of the full-length hPGC1. 
Reagent Amount Cycle/Temperature Time 
DNA (50 ng/l) 2 l 98 C 30 s 
Buffer HF (5X) 40 l 98 C 
55 C     40 x 
72 C 
7 s 
dNTP (10 mM) 4 l 20 s 
Primers (10 M) 10 l 30 s 
Phusion polymerase (2U/l) 2 l 72 C 2 min 
mQH2O 142 l 72 C 
Total volume 200 l  
 
Table 10. Primers used for PCR amplification of the full-length hPGC1. 
Primers for hPGC1α-FL amplification (5’-3’): 
hPGC1a_FL_BamHI_m2hF ATTGGATCCATGGCGTGGGACATGGCA 
hPGC1a_FL_CPEC_m2hR CCCCAAGGGGTTATGGTAGGATCCTTACCTGCGCAAGCTTCT 
 
Construct containing the N-terminal 3xFLAG-fusion of the synthetic hPGC1α-LXXLL 
domain was prepared by subcloning from pUC57-hPGC1α-LXXLLsyn plasmid obtained 
from BioBasic (BioBasic Inc. Unionville, Canada) into pCoAT7H3F vector after the 3xFLAG 
site using NcoI/BamHI restriction enzymes. hCAR-LBD was inserted into the pCoAT7H3F-
hPGC1α-LXXLLsyn plasmid as previously described for the other constructs. 
 
Inserts were ligated into pCoAT7H3F vector using T4 DNA ligase (New England Biolabs, 
Ipswich, USA) with overnight incubation at 16 
o
C. The ligation mixtures were transformed 
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into E. coli XL-10 strain and plated on LB agar plates containing 100 g/ml carbenicillin 
(Carbenicillin DIRECT, UK). 
 
4.5 Analysis of the constructs 
 
The colonies were screened with colony PCR, which the condition is shown in Table 11. 
Colonies were grown in 0.5 ml LB media pre-cultures for 3 – 4 hours at 37 oC. PCR was 
performed using Dream taq polymerase (Fermentas, Thermo Fisher Scientific Inc., Waltham, 
USA) with 0.5 l of pre-cultures as template. Primers used in the reaction were pCoA-
Hat_seqF for pCoAT7H3F-hCAR-LBD-hPGC1 constructs and pCoA-3xFlag_seqF for 
pCoAT7H3F-hPGC1 constructs. T7termR was used for both reactions as 3’-primer. Primers 
used in the PCR are shown in Table 12. The positive colonies were inoculated and grown in 
20 ml of super broth (SB) media containing carbenicillin. The constructs were extracted from 
the cultures using midiprep DNA extraction kit (Qiagen). Constructs were further analyzed 
with restriction enzymes selected to cut out the insert using the cloning sites or to digest the 
construct into well detectable fragments in gel electrophoresis. The correct constructs were 
confirmed by sequencing at DNA Analysis Facility of Yale University, USA. 
 
Table 11. Colony PCR conditions.  
Reagent Amount Cycle/Temperature Time 
Culture from a colony 0.5 l 94 C 2 min 
Dream taq buffer (10 x) 2.0 l 94 C 
55 C     35 x 
72 C 
30 s 
dNTP (10 mM) 0.4 l 30 s 
Primers (10 M) 0.4 l 1 – 3 min* 
Dream taq polymerase (2U/l) 0.1 l 72 C 5 min 
mQH2O 16.6l 72 C 
Total volume 20.0 l  
* Amplification time was 1/kb min for small PCR products (1000 bp) and 3 min/kb for big PCR products 
(> 2500 bp). 
 
Table 12. Primers used in colony PCR and for sequencing. 
Name Sequence (5’-3’) 
pCoA-Hat_seqF GAAAGATCATCTGATTC 
pCoA-3xFlag_seqF GGACTACAAAGACCACG 
T7termR GCTAGTTATTGCTCAG 
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4.6 Mini scale protein expression tests 
 
Constructs were transformed into E.coli BL21(DE3)-Gold (Stratagene, Agilent Technologies, 
Inc., Santa Clara, USA), BL21(DE3)-pRARE and OrigamiB(DE3) (Novagen EMD Millipore, 
Billerica, USA) strains for mini-scale protein expression tests. The protein expression tests 
were performed as mini-scale expression tests in a 2 ml cultures. Different expression 
conditions were tested (Table 13). Pre-cultures were grown overnight at 37 C 200 rpm and in 
the morning OD600 were measured. The pre-cultures were diluted to OD600 0.1 with media 
containing half amount of antibiotics, 50 g/ml carbenicillin and 17 g/ml chloramphenicol 
and incubated at 37 C 200 rpm until OD600 reached 0.6 – 0.8. Protein expression was induced 
with isopropyl-β-D-1-thiogalactopyranoside (IPTG) and the culture was divided and further 
incubated at 18 and 25 C overnight at 200 rpm shaking. Cells were harvested by 
centrifugation at 4300 rpm 30 min and pellets were resuspended in lysis buffer (1 x PBS with 
250 mM NaCl, 5 % glycerol, pH 7.0). Lysis buffer volumes were calculated according to the 
density of the cultures. 40 l of the cell suspension was pipetted to microcentrifuge tubes 
where 10 l of 5 x protein loading buffer (156 mM Tris-HCl pH 6.8, 5 % SDS, 25 % glycerol, 
25 % sacharose, 1mM TCEP, 0.1 % bromphenol blue) was added. Cells were lysed at 99 C 
for 10 min and centrifuged at 14680 rpm for 2 min. The proteins from the supernatants were 
separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). To 
the 12 % or 15 % SDS-PAGE gel 5 – 10 l of the supernatant was loaded depending on the 
size of the combs used. 
 
Table 13. Different strains and conditions for mini scale protein expression tests. 
Expression conditions 
E. coli strains BL21(DE3) Gold 
BL21(DE3) with pRARE 
OrigamiB(DE3) 
OrigamiB(DE3) with pLEMO 
Incubation time and 
temperature 
2 h at 37 
o
C 
overnight at 25
 o
C 
overnight at 18 
o
C 
4, 18.5 & 24 h at 30 
o
C (only with 
pLEMO) 
Amount of IPTG titration (0, 0.2, 0.4, 0.6, 0.8 and 1 mM) 
1 mM 
Growth medium LB 
N-Z-amine 
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OrigamiB(DE3) was tested with and without pLEMO plasmid (Xbrane Bioscience AB, 
Stockholm, Sweden) for regulating the T7 RNA polymerase by T7 lysozyme induced with 
rhamnose (Figure 12). 
 
 
Figure 12. Schematic overview of pLemo system in protein production. Rhamnose is used to induce the T7 
lysozyme (T7LysY), which inhibits the T7 RNA polymerase (T7RNAP) and thus regulating the levels of 
T7RNAP and the expression of the target protein. In the experiment pCoAT7H3F vector was used instead 
of pET (Wagner et al. 2008). 
 
The pLemo system was tested for pCoAT7H3F-CAR-LXXLL, pCoAT7H-CAR-3F-RS and 
pCoAT7H3F-CAR according to Xbrane protocol (http://www.xbrane.com/files/documents 
/Protocol_Xbrane_Lemo_System.pdf). The pLemo plasmid was transformed into 
OrigamiB(DE3) with pCoAT7H3F constructs using heat shock and plated in LB agar plates 
containing 100 g/ml of carbenicillin and 34 g/ml of chloramphenicol to amplify and 
maintain the plasmids. One colony of each construct was inoculated into 2 ml of N-Z-amine 
media with antibiotics and grown overnight. The next day 0.2 ml of starter cultures was 
inoculated to expression 10 ml cultures of N-Z-amine with 50 g/ml of carbenicillin and 17 
g/ml of chloramphenicol containing 0, 0.1, 0.25, 0.5, 0.75, 1.0 and 2.0 mM of L-rhamnose. 
In addition a culture without L-rhamnose and without IPTG was included as control. The 
cultures were further incubated at 30 C for 4.5 h until OD600 reached 0.4 – 0.8. The protein 
expression was induced with 40 l of 100 mM IPTG to a final concentration of 0.4 mM IPTG 
in the cultures. The cultures were then incubated at 30 C and 3 ml of cultures was collected 
after 4, 18.5 and 24 h. Cells were harvested by centrifugation 4300 rpm for 30 min at 4 C 
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after OD600 measurement for the calculation of lysis buffer. The protein samples were 
prepared as previously described. 
 
4.7 Western blot 
 
Western blotting was used to detect the expressed proteins. Rabbit anti-FLAG antibody 
conjugated to DyLight
TM
 800 dye for FLAG fusion proteins and rabbit anti6xHis antibody 
conjugated to DyLight
TM
 680 dye for 6xHis conjugated proteins (Rockland Immunochemicals 
Inc., Gilbertsville, USA) were used for the detection of 3xFLAG and HAT recombinant 
proteins, respectively.  
 
Western blot was performed from sonicated and centrifuged E. coli cultures from the mini 
scale expression tests. The expression cultures were suspended in lysis buffer and stored at - 
20 C. The cultures were sonicated on ice with 25 % amplitude and 2 s pulse on and 2 s pulse 
off for 1 min using Sonics sonicator tapered four-head probe (Vibra Cell
TM
, Sonics & 
Materials, Inc., Newtown, USA). From the sonicated lysates 50 l were taken as crude lysate 
samples and the rest were centrifuged 20 124 x g (15 000 rpm) for 40 min at 4 C (Heraus 
Megafuge 1.0R, Thermo Fisher Scientific Inc., Waltham, USA). Protein concentrations were 
measured from the crude lysates and supernatants using Bio-Rad protein assay (Bio-Rad 
Laboratories, Hercules, USA). Measurement was performed with 5 l of samples and 1 ml of 
Bio-Rad protein assay reagent. The samples were incubated for 5 min and absorbance was 
measured at 595 nm using Genesys 10 uv spectrophotometer (Thermo electron corporation, 
Thermo Fisher Scientific Inc., Waltham, USA). The protein concentrations were calculated 
using equation from previously measured bovine serum albumin standard curve. 
 
5 and 10 g of proteins were loaded from the supernatant samples and 2.5 g from the crude 
lysate samples to a 10.5 % SDS-PAGE gel that gel was run at 180 V for 1 h. After the gel 
electrophoresis, proteins were transferred to a PVDF membrane with at 100 V for 50 min and 
the membranes were blocked using 3 % non-fat milk in PBS overnight at 4 C. Antibodies 
were diluted to 3 % milk in PBS to 1:10 000 and anti-FLAG was tested also with 1:15 000 
dilution. Membranes were incubated 1 h with antibodies at room temperature and washed 
with PBS containing 0.1 % Tween-20. Membranes were stored in PBS and scanned using 
 42 
Odyssey

 imager (LI-COR Biosciences, Lincoln, USA) with 700 nm and 800 nm excitation 
filter. 
 
4.8 Co-purification of hCAR and hPGC1 domains 
 
Protein purification of hCAR and hPGC1α domains was performed from BL21(DE3)-pRARE 
E. coli strain. Purification was tested for hCAR-RS with two different expression conditions 
such as 2 h at 37 C and overnight at 20 C. Proteins were expressed in 10 ml volumes with 
addition of 1 mM IPTG when OD600 reached 0.4-0.6 and 5 ml volumes for negative 
expression controls without IPTG. Purification was performed using CAR purification buffer 
including 50 mM Tris-HCl, 100 mM NaCl and 20 % glycerol with pH 8.0 and using PBS 
buffer including 1x PBS, 250 mM NaCl and 5 % glycerol with pH 7.0. Proteins were purified 
using Co
2+
 -chelated affinity resin (TALON
®
 Superflow
TM
 Metal Affinity Resin, Clontech, 
Saint-Germain-en-Laye, Francen). In addition, purification was performed using protease 
inhibitors in the CAR purification buffer in order to determine whether there was protease 
activity occurring during the purification process. 
 
Expression cultures were resuspended in purification buffer according to their OD600 values 
and were sonicated for 1 min with pulse on 2 sec and off 2 sec with 25 % amplitude on ice. 40 
l of the sonicated samples were taken as a crude lysate sample for SDS-PAGE analysis. The 
rest of the sample was centrifuged at 15 000 rpm for 40 min at + 4 C. Supernatant was 
collected and 40 l was taken for SDS-PAGE. The affinity resin was equilibrated by repeated 
(3x) washing with 10x bead volume of purification buffer. 10 l of beads were used to purify 
the proteins from 10 ml cultures. Supernatant was pipetted to the microcentrifuge tube 
containing the beads and the proteins were allowed to bind to the beads for 1 h at + 4 C on a 
platform shaker. The samples were centrifuged at 700 x g for 5 min at + 4 C and 40 l of the 
supernatant was taken as “flow-through” sample for SDS-PAGE indicating the amount of 
proteins, which did not bind to the beads. Rest of the supernatant was removed from the 
beads. The beads were washed three times with 10 x beads volume of purification buffer. 
From the first faction 40 l was taken for SDS-PAGE. The beads were resuspended with 10 
l of purification buffer and 20 l of 2x protein loading buffer was added. For the 40 l SDS-
PAGE samples 10 l of 5x protein loading buffer was added. The samples were heated at 99 
C for 10 min and centrifuged at 14 680 rpm for 5 min. From the crude lysate and bead 
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samples 5 l and from the supernatant, flow-through and wash samples 10 l was loaded to 
the 12 % SDS-PAGE gel. SDS-PAGE was run at 200 V for 50 min. 
 
4.9 Cell culturing and reporter gene assays 
 
Reporter gene assay was used to investigate the effect of the full-length hPGC1 for hCAR 
activation. MCF-7 and C3A cell lines were used in the reporter gene assays. Cell cultures 
were incubated at 37 C with 5 % CO2. Transfections were performed using 
polyethyleneimine (PEI, Polysciences Inc., Warrington, USA) as DNA carrier. The plasmids 
used in the reporter gene assays are shown in Table 14. The luciferase activities were divided 
with the protein concentrations measured using Bradford method from every sample in order 
to decrease the variation caused by the cell amounts between different wells. 
 
Table 14. Plasmids used in the reporter gene assays. 
Plasmid Origin 
pGL3-empty Promega Corporation, Madison, WI, USA 
pGL3-PBREM Dr. Honkakoski (UEF, Kuopio, Finland) 
pSG5-hCAR FL Dr. Honkakoski (UEF, Kuopio, Finland) 
pcDNA3-hPGC1α FL Dr. Billas (IGBMC, Strasbourg, France) 
 
4.9.1 Optimization of reporter gene assay 
 
Different amounts of plasmids and DNA-PEI ratios were tested for optimization of reporter 
gene analysis. 1:1 and 1:2 DNA-PEI ratios were tested to optimize the transfection. The 
optimal amount of hCAR was determined by titration with constant amount (500 ng) of 
PBREM response element using ratios shown in Table 15. pGL3-plasmid without PBREM 
response element was used as a control alone and with pSG5-hCAR. 
 
Table 15. Titration of CAR with 500 ng of PBREM using MCF-7 and C3A cells. 
pSG5-hCAR FL PBREM-hCAR ratio 
50 ng 10:1 
100 ng 5:1 
250 ng 2:1 
500 ng 1:1 
1000 ng 1:2 
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After the amount of hCAR was optimized, titration of hPGC1 was performed. The titration 
using MCF-7 cells is summarized in Table 16. Two different hCAR concentrations were 
tested, because both 50 ng and 100 ng in the titration for hCAR gave similar level of high 
activation. 
 
Table 16. Titration of PGC1 with 50 ng and 100 ng of CAR using MCF-7 cells. 
pcDNA-hPGC1α 
hPGC1-hCAR- ratio 
50 ng of hCAR 100 ng of hCAR 
10 ng 20 ng 1:5 
25 ng 50 ng 1:2 
50 ng 100 ng 1:1 
100 ng 200 ng 2:1 
200 ng 500 ng 5:1 
500 ng 1000 ng 10:1 
 
The titration of hPGC1 was performed using C3A cells with 500 ng hCAR and DNA-PEI 
ratio of 1:1, which is summarized in Table 17. The maximum hPGC1-hCAR ratio was 2:1 
due to the high concentration of total DNA in the cells. Therefore the 5:1 and 10:1 ratios used 
in the PGC1 titration in MCF-7 cells were not included.  
 
Table 17. Titration of hPGC1 with 500 ng of hCAR in C3A cells. 
pcDN-hPGC1 hPGC1α-hCAR- ratio 
50 ng 1:10 
100 ng 1:5 
250 ng 1:2 
500 ng 1:1 
1000 ng 2:1 
 
For the reporter gene assays the statistical analysis was performed using GraphPad Prism 
software (GraphPad Software Inc., La Jolla, USA). Results were analyzed using paired, two-
tailed Students’ t-test with 95 % of confidence interval. In the hCAR titration experiments the 
samples containing CAR were compared to the PBREM response element alone and in the 
hPGC1α titration the samples were compared to PBREM response element with hCAR alone. 
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5 RESULTS 
 
5.1 Comparison of human and mouse PGC1 homology using BLAST 
 
A comparison for human and mouse PGC1 homology was done in order to determine its 
conservation of in different species. A sequence alignment was performed using NCBI 
BLAST tool for nucleotide as well as amino acid sequences. The created alignments are in the 
Appendix B. The homology in the amino acid sequences for full-length PGC1 orthologues 
was 94 %, for LXXLL domain 93 % and for RS domain 97 % (Table 21). All three LXXLL 
motifs, LLAVL, LKKLL and LLKYL, were conserved and also the RS domain, RS motif and 
RRM motif were unaltered. However, the PPAR interaction domain contained six 
substitutions. 
 
Table 21. Comparison of human and mouse PGC1 amino acid sequence homology for the full-length, 
LXXLL and RS domains. 
Sequence Length Homology 
PGC1 full-length 797 aa 94 % 
LXXLL motif  506 aa 93 % 
RS domain  291 aa 97 % 
 
5.2 Analysis of the constructs 
 
Colonies were screened using colony PCR with primers amplifying the insert inside the 
vector. The sizes of PCR product are shown in Table 18. pCoAT7H3F-hPGC1 constructs 
were amplified using a primer annealing to the FLAG-site and pCoAT7H3F-hCAR-LBD 
constructs using a primer annealing to the HAT-site. From every construct that produced the 
correct PCR positive clones were identified.  
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Table 18. Sizes for the colony PCR products. 
Construct Size of the colony 
PCR product # Name 
1 pCoAT7H3F-CAR 1109 bp 
2 pCoAT7H3F-CAR-FL 3505 bp 
3 pCoAT7H3F-CAR-LXXLL 2635 bp 
4 pCoAT7H3F- CAR-RS 1987 bp 
5 pCoAT7H3F-CAR-LXXLLsyn 1566 bp 
6 pCoAT7H3F-FL 2550 bp 
7 pCoAT7H3F-LXXLL 1669 bp 
8 pCoAT7H3F-RS 1013 bp 
9 pCoAT7H3F-LXXLLsyn 592 bp 
 
The positive clones from the colony PCR were further analyzed with restriction enzymes. The 
plasmids were extracted using miniprep columns (Qiagen, Hilden, Germany) and digested 
using restriction enzymes, which results in fragments detectable in gel electrophoresis and 
differs from a digestion profile of an empty vector. The correct fragments of the digestions are 
shown in table 19. The correct digestion profiles were obtained in every construct and from 
these, depending on the total number of candidate constructs, one or two constructs were 
sequenced. 
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Table 19. Sizes of the expected fragments in the restriction analysis of the constructs. 
Construct Restriction enzymes 
used in plasmid digests 
Expected fragments 
(bp) # Name 
1 pCoAT7H3F-CAR BamHI/NdeI 
NcoI 
746 & 5396 
56, 467 & 5619 
2 pCoAT7H3F-CAR-FL BamHI/NdeI 
NcoI 
746 & 7784 
56, 467, 1518 & 6489 
3 pCoAT7H3F-CAR-LXXLL BglII 318, 465, 1435 & 5442 
4 pCoAT7H3F- CAR-RS BamHI/NdeI 
NcoI 
746 & 6266 
56, 467 & 6489 
5 pCoAT7H3F-CAR-LXXLLsyn BamHI/NdeI 
NcoI 
746 & 5840 
56, 467 & 6063 
6 pCoAT7H3F-FL XbaI 
NcoI/XbaI  
HindIII/XhoI 
1182 & 7348 
298, 884, 1220 & 5390 
2411 & 6119 
7 pCoAT7H3F-LXXLL NcoI 
EcoRI/SalI 
1518 & 5404 
820 & 6102 
8 pCoAT7H3F-RS NcoI/XbaI 
HindIII/XhoI 
876 & 5398 
893 & 5381 
9 pCoAT7H3F-LXXLLsyn MluI/XhoI 
NdeI/XbaI 
BamHI/XbaI 
BamHI 
1123 & 5463 
1414 & 5172 
1406 & 5180 
6586 (linearization) 
 
The sequencing results confirmed that pCoAT7H3F-hPGC1-LXXLL, pCoAT7H3F-
hPGC1-RS, pCoAT7H3F-hCAR-LBD, pCoAT7H3F-hCAR-LBD-hPGC1-LXXLL and 
pCoAT7H3F-hCAR-LBD-hPGC1-RS constructs were correct. The pCoAT7H3F-hPGC1-
FL and pCoAT7H3F-hCAR-LBD-hPGC1-FL did not contain full-length hPGC1 insert. 
 
5.3 Mini scale protein expression tests 
 
Different E. coli strains and conditions were tested to optimize the protein expression for 
hPGC1-LXXLL, hPGC1-RS, hPGC1-LXXLLsyn with and without hCAR-LBD in 
pCoAT7H3F co-expression vector. In addition, hCAR alone in pCoAT7H3F vector was 
tested. The protein sizes are shown in Table 20 3xFLAG-linked hRXR cloned in pCoAT7H3F 
vector was taken as a positive control for expression. Proteins from the expression cultures 
were separated using denaturing gel electrophoresis, SDS-PAGE.  
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Table 20. Size of the HAT and 3xFLAG fusion proteins. 
Protein Size (kDa) Size without tag 
(kDa) 
HAT-CAR LBD 32.4 28.2 
3xFLAG-LXXLL 60.2 56.2 
3xFLAG-RS 38.9 35.0 
3xFLAG-LXXLLsyn 21.0 17.0 
3xFLAG-RXR 30.7 26.7 
 
The SDS-PAGE analysis showed that the expression level of the studied proteins was low. 
Only LXXLLsyn was clearly visible in the gels as a 25 kDa band (Figure 13). Some 
indications of protein expression were detected with RS and CAR. CAR seemed to be around 
25 to 30 kDa and therefore the co-expression of synthetic LXXLL and CAR was difficult to 
distinguish (Figure 13). The wild-type LXXLL was not detected in any of the expression 
tests. hRXRα was expressed using the same conditions as for the other proteins. 
 
     
Figure 13. SDS-PAGE of pCoAT7H3F-LXXLLsyn protein  Figure 14. SDS-PAGE of pCoAT7H3F-CAR 
expression test for five different colonies. Negative control -LXXLLsyn protein expression test for two 
samples without IPTG are indicated with minus. 15 % gel different colonies. 12 % gel was used. 
was used. LXXLLsyn indicated with black rectangle.  
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5.4 Western blot 
 
Western blot was performed with anti-FLAG and anti-6xHis antibodies in order to detect 
3xFLAG-tagged hPGC1 proteins and HAT-tagged hCAR LBD. 3xFLAG-hRXRα and 
6xHis-VDR were taken as control samples. 3xFLAG-hRXRα was shown in SDS-PAGE with 
Coomassie Blue staining and therefore it was included as positive control for anti-FLAG. 
6xHis-VDR was taken as a control for anti-6xHis to compare binding of the antibody to HAT 
and 6xHis. 
 
Anti-6xHis was unable to detect both the HAT-tagged hCAR or the 6xHis-VDR. 3xFLAG 
fusion proteins were detected from the protein expression test samples (Figure 15 A). 
3xFLAG-hRXRα was detected as a clear band and it was around 35 kDa (lane 8). The 
3xFLAG-tagged LXXLL region is 60 kDa and there were various bands visible in the 800 nm 
scan. However, a band around 55-58 kDa visible in LXXLL and faintly in hCAR-LXXLL 
samples (lanes 2 and 3), which was not present in the other samples. The RS samples 
contained a band around 40 to 46 kDa, which was consistent with all the samples (lanes 4 and 
5). 
 
 
Figure 15. Western blot (A) and Coomassie Blue staining (B) for 10 g of proteins from supernatant 
fractions. Western blot was performed with anti-FLAG antibody at a dilution of 1:15000, scanned at 800 
nm wavelength. 1) protein marker, 2) LXXLL, 3) CAR-LXXLL, 4) RS 2, 5) CAR-RS, 6) CAR 10, 7) 
LXXLLsyn, 8) RXR, 9) 6xHis-VDR, 10) RS 3, 11) RS 4, 12) RS 5, 13) CAR 3, 14) CAR 6. Adobe 
Photoshop was used to enhance the lanes by changing the contrast levels of the image histogram (A, lanes 
2-6 and 9-14). 
 
The same supernatant samples used in the western blot were run on 10 % SDS-PAGE with 10 
µg of protein and stained with Coomassie Blue (Figure 15 B). Amount of protein in the 
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hRXRα sample was reduced to 2 µg due to the intense band in western blot. Only hRXRα 
(lane 8) and LXXLLsyn (lane 10) were clearly visible on the gel using this staining. In 
addition, the purified 6xHis-hVDR had shown a clear band, which was not detectable in the 
Western blot membrane and this shows that the anti-6xHis antibody does not seem to work. A 
weak band of 30 to 32 kDa was visible in hCAR-LXXLL sample (lane 3), in CAR-RS sample 
(lane 6) and in CAR samples (lanes 13 and 14), which seems to be hCAR. LXXLL and RS 
could not be clearly distinguished from the other E. coli proteins. 
 
Due to the weak detection of the recombinant proteins in the supernatant samples, western 
blot was repeated using crude lysate samples. Western blot was performed with 2.5 µg of 
protein and Coomassie Blue staining was performed with 5 µg of protein for the same 
samples (Figure 16). In the hRXRα sample, only 1 µg of protein was taken for western blot 
and 2 µg for Coomassie Blue staining. There was a 55-58 kDa band visible in LXXLL sample 
and very weakly in CAR-LXXLL sample (Figure 16 A, lane 3 and 4), similar to supernatant 
samples. RS was clearly visible in all RS and CAR-RS samples with 40 to 46 sized band on 
the Western blot membrane and Coomassie gel (Figure 16 A and B, lanes 5 – 10). CAR was 
visible in CAR-RS samples around 28 to 30 kDa with Coomassie Blue staining (B, lanes 9 
and 10). LXXLLsyn was weakly detected around 26 to 28 kDa with Western blot and 
Coomassie Blue staining (A and B, lane 11). hRXRα was clearly visible around 32 to 35 kDa 
with western blot and Coomassie staining (A and B, lane 12). 
 
 
Figure 16. Western blot and Coomassie Blue staining for crude lysate fractions. A) Western blot was 
performed with 2.5 g of proteins with anti-FLAG antibody at a dilution of 1:25000 scanned at 800 nm 
wavelength and B) Coomassie staining was performed for 5 g of proteins. Protein were separated with 10 
% SDS-PAGE. 1) Empty, 2) protein marker, 3) LXXLL, 4) CAR-LXXLL, 5) RS 2, 6) RS 3, 7) RS 4, 8) RS 
5, 9) CAR-RS A, 10) CAR-RS B, 11) LXXLLsyn, 12) RXR 1 g in western blot and 2 g in Coomassie 
staining. 
 51 
 
5.5 Co-purification of hCAR and hPGC1 domains 
 
Purifications of hCAR-hPGC1-RS, hCAR-hPGC1-LXXLL and hCAR-hPGC1-
LXXLLsyn complexes and hCAR alone were performed on lysates derived from 10 ml 
cultures using metal affinity beads binding to the HAT fused to hCAR. Expression was 
performed for 2 h at 37 ºC or overnight at 20 ºC. hCAR-hPGC1-RS purification was 
performed using CAR purification buffer with pH of 8.0 for both expression conditions 
(Figure 17). The theoretical size for CAR with HAT tag is around 32 kDa and CAR was 
purified as a clear fraction around 25 to 30 kDa and. However, there were three bands 
scattered around that size and the bands were intensive in the purified fraction (lanes 7 and 
13). A band of around 40 kDa was detected in crude lysate and bound protein samples with 20 
ºC overnight expression (lanes 9 and 13). This protein band may represent hPGC1α-RS, 
which has a theoretical size of 39 kDa. However, this band was absent from the 2 h at 37 ºC 
expression samples. In addition, purification for the same expression cultures was performed 
using PBS buffer with pH of 7.0 in order to determine the effect of the buffer to the 
purification. There were no clear advantages for using PBS compared to CAR purification 
buffer (data not shown) and therefore for the rest of the purifications CAR purification buffer 
was used. Expression level of the desired proteins seemed to be higher at 20 ºC with overnight 
incubation compared to 2 h at 37 ºC expression condition.  
 
 
Figure 17. Purification of CAR-RS protein complex using CAR purification buffer. Cultures without 
IPTG were included as negative expression controls, indicated with “–“ in crude lysate samples. Other 
purification steps were performed only for positive expression samples. CL = crude lysate, S = 
supernatant, FT = flow-through, W = wash, Beads = bound protein. 
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Due to the multiple bands in the 25 to 30 kDa range, purification using protease inhibitors 
was tested to determine whether the bands could be proteolysed fragments of hCAR. The 
purification was performed in the presence and absence of hPGC1α-LXXLLsyn domain. 
However, the three bands were also detected in the presence of protease inhibitors and 
therefore they may be formed during the expression in E. coli (Figure 18). Comparing the 
purifications of hCAR in the presence and absence of hPGC1α-LXXLL, there seems to be 
only small difference. The expression in hCAR-LXXLL sample is lower and there are no 
additional bands indicating the expression of the LXXLL domain. However, in the 
purification samples of LXXLLsyn with hCAR, the expression level is higher than with the 
other co-expressed proteins. Only with CAR-LXXLLsyn sample the expression can be 
detected from the crude lysate samples with IPTG (Figure 18, lane 9). Moreover, there is a 
strong band around 55 to 60 kDa, which is not visible with the other proteins. It appeared to 
be a double band, however the lower band is hardly detectable. 
 
 
Figure 18. Purification of CAR-PGC1α-LXXLL, CAR-PGC1α-LXXLLsyn and CAR. Purification was 
performed from 10 ml cultures at 20 
o
C with overnight incubation using CAR purification buffer with 
protease inhibitors. 
 
5.6 Cell culturing and reporter gene assays 
 
Cell culturing was performed using MCF-7 and C3A cell lines for the reporter gene assays. 
Microscopic images were taken to visualize the morphology of the two different cell lines 
(Figure 19). Both are epithelial cells and grow adherent, attached to the culturing dishes. C3A 
cells are more round-shaped compared to MCF-7 cells. 
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Figure 19. Microscopic images of cell lines used in the assays. A) MCF-7 cells and B) C3A cells taken with 
100-fold magnification. 
  
In the reporter gene assays DNA-PEI ratios of 1:1 and 1:2 were tested and the optimal amount 
of hCAR and hPGC1 plasmids were selected by titration. First hCAR titration was 
performed and then hPGC1 with selected optimal hCAR amount using MCF-7 cell line. 
Empty pGL3 vector with and without hCAR and pGL3-tk-luc-PBREM plasmids were 
included as controls. The results were normalized to protein amounts measured using 
Bradford method. The result showed that empty pGL3 plasmid did not yield luciferase 
activity with or without CAR with normalized activity of around 100 units in both DNA-PEI 
ratios of 1:1 and 1:2 (Figure 20). The luciferase activity of response element with luciferase 
gene, tk-luc-PBREM, alone yielded 2-fold and 1.2-fold increase compared to the samples 
without the luciferase gene with DNA-PEI 1:1 ratio and 1:2 ratio, respectively. The activities 
with 1:1 ratio were around 3- to 4.5-fold higher compared to 1:2 ratio in the samples 
containing hCAR. Addition of 50 ng of CAR increased the activity by 5-fold compared to 
PBREM alone in the DNA-PEI 1:1 samples. The activity of hCAR declined in a dose 
dependent manner with 1000 ng of hCAR the luciferase activity being only 2-fold compared 
to PBREM alone. Similar trend was detectable with DNA-PEI 1:2 samples. 
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Figure 20. Luciferase activity for CAR titration using MCF-7 cells with mean and standard deviation (n = 
3). Titration was performed with DNA-PEI ratios 1:1 and 1:2 and with 500 ng of PBREM or empty 
vector. Titration of CAR was performed once using triplicates. Samples containing CAR were compared 
to PBREM alone with t test. * P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
 
The titration of hPGC1 was performed using 50 and 100 ng of hCAR, in order to verify the 
results showing higher activity of 50 ng of hCAR. DNA-PEI ratio of 1:1 was chosen for these 
transfections. With 50 ng of hCAR the activity was 1.5-fold compared to PBREM alone 
(Figure 21). The activity with 100 ng of CAR was 3-fold compared to PBREM alone. The 
activity peaked at 2.7-fold with 200 ng of hPGC1α in assay with 50 ng of hCAR. With 100 ng 
of hCAR, hPGC1α increased the activity to the maximum by only approximately 2-fold using 
100 ng of hPGC1α. The further increase of hPGC1α seemed to decrease the activity in a dose 
dependent manner but with 50 ng of hCAR the amounts of hPGC1α did not seem to affect the 
activity levels profoundly. 
 
 55 
CAR 50 ng
L
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
P
B
R
E
M
P
B
R
E
M
 +
 C
A
R
P
G
C
1a
 2
0 
ng
P
G
C
1a
 5
0 
ng
P
G
C
1a
 1
00
 n
g
P
G
C
1a
 2
00
 n
g
P
G
C
1a
 5
00
 n
g
P
G
C
1a
 1
00
0 
ng
0
500
1000
1500
2000
2500
** **
**
** **
CAR 100 ng
L
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
P
B
R
E
M
P
B
R
E
M
 +
 C
A
R
P
G
C
1a
 2
0 
ng
P
G
C
1a
 5
0 
ng
P
G
C
1a
 1
00
 n
g
P
G
C
1a
 2
00
 n
g
P
G
C
1a
 5
00
 n
g
P
G
C
1a
 1
00
0 
ng
0
1000
2000
3000
4000
5000
**
**
*
*
 
Figure 21. Luciferase activity for PGC1α titration using MCF-7 cells with mean and standard deviation (n 
= 3). Titration was performed with 50 ng and 100 ng of CAR with 500 ng of PBREM using DNA-PEI 
ratios 1:1. Experiment was performed twice, data from one experiment is shown. Samples containing 
PGC1α were compared to PBREM + CAR with t test. * P<0.05, **P<0.01 
 
To compare the results in different cell lines, the reporter gene assays for hCAR titration and 
hPGC1α titration were also performed in C3A. The hCAR titration was performed as 
previously described for MCF-7. The DNA-PEI ratio of 1:1 resulted also in higher activities 
compared to 1:2 ratio, as seen in MCF-7 cells. The highest measured activity was 3.5-fold. On 
the contrary to best condition where 50 ng of hCAR was used in MCF-7 cells, 500 ng of 
hCAR was required to yield the highest luciferase activity with 5-fold increase compared to 
PBREM alone. The empty pGL4 vector in the presence and in the absence of hCAR yielded 
approximately the same level of luciferase activity. 
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Figure 22. Luciferase activity using for CAR titration C3A cells with mean and standard deviation (n = 3). 
Titration was performed with DNA-PEI ratios 1:1 and 1:2 and with 500 ng of PBREM or empty vector. 
Titration of CAR was performed twice times with triplicates, data from one experiment is shown. Samples 
containing CAR were compared to PBREM alone with t test. * P<0.05, **P<0.01, ***P<0.001 
 
The titration of hPGC1α in C3A cells was performed with 500 ng of hCAR using DNA-PEI 
ratio of 1:1. Two different amounts of PBREM were tested in order to determine whether 500 
ng was optimal for the assays. First, the titration using 500 ng of PBREM was performed as in 
the previous assays and then the assay was repeated using 100 ng of PBREM (Figure 23). In 
the assay with 500 ng of PBREM, the activity of hCAR was only 2-fold compared PBREM 
alone. PBREM resulted in higher activity compared to the previous assays (Figures 21 and 
22). The luciferase activity increased only 1.5-fold to its maximum with 100 ng and 1000 ng 
of hPGC1α compared to hCAR with PBREM. With 100 ng of PBREM, the activity of hCAR 
was 2.5-fold compared to PBREM alone. Moreover, hPGC1α increased the activity by 5.7-
fold with 1000 ng and 3.8-fold with 500 ng compared to hCAR with PBREM. Untransfected 
cells were taken as a control to determine the background signal of the assay. The activity of 
cells alone was around 60 absolute light units, which was at the same level as in the samples 
with 100 ng of PBREM alone, thus in C3A no detectable activity that may come from cells 
was observed. 
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Figure 23. Normalized luciferase activity for PGC1α titration using C3A cells with mean and standard 
deviation (n = 3). Titration was performed using 500 ng of CAR with 500 ng and 100 ng of PBREM. DNA-
PEI ratio was 1:1. Experiment was performed three times with triplicates using 500 ng of PBREM and 
once using 100 ng of PBREM, data from one experiment is shown. Samples containing PGC1α were 
compared to PBREM + CAR with t test. * P<0.05, **P<0.01, ***P<0.001 
 
6 DISCUSSION 
 
6.1 Comparison of human and mouse PGC1 homology using BLAST 
 
The comparison of the homology between human and mouse PGC1 orthologues was 
performed in order to determine the possible differences. Shiraki and colleagues (Shiraki et al. 
2003) performed their experiments using mouse PGC1 and in this thesis hPGC1 was used. 
There may be differences in the responses with different species, for example human and 
mouse CAR respond in different ways to some known hCAR ligands. 
 
The results showed that the similarity between human and mouse full-length PGC1 is 94 % 
LXXLL motif 93 % and RS domain 97 %. The RS domain seems to be well conserved due to 
the high similarity. However, the three LXXLL motifs are all unchanged and also the RS 
domain, but the PPAR interaction motif contains six substitutions. The alterations between 
the two PGC1 sequences were for the most part in the regions, which do not contain 
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important interaction surfaces or functional properties. Therefore it could be presumed that 
the difference between human and mouse PGC1 is not influential for the interaction studies. 
6.2 Molecular cloning of the recombinant protein constructs 
 
hCAR LBD and LXXLL and RS domains of human PGC1 were cloned into co-expression 
vector using classical cloning. Due to intrinsic NcoI site the cloning of the full-length 
hPGC1 was attempted with the subsequent insertion of both, LXXLL-NcoI and RS-
BamHI/NcoI, into pCoAT7H3F-vector digested with NcoI and BglII. Except this the 
pCoAT7H3F-hPGC1 full-length construct, all other designed constructs were successfully 
cloned. Unfortunately, there is no data indicating the reason for this failure. The additional 
future approaches to obtain the full-length hPGC1α expression construct may be in using 
ligation independent cloning techniques. However, the current wild-type cDNA fragments 
that generated the LXXLL and RS domain construct show problems in expression level and 
protein solubility that is to be expected also for full-length hPGC1α due to the large size and 
the lack of chaperones in the bacterial expression system. 
 
6.3 Analysis of the constructs 
 
The constructs were analyzed using colony PCR, restriction enzymes and sequencing. Colony 
PCR is an efficient, fast and relatively cheap method for screening a large number of colonies. 
A vector-specific T7 terminator and an insert-specific 3xFLAG or HAT primers were used in 
the PCR to amplify the DNA containing the inserts. Colony PCR identified the correct sized 
product for pCoAT7H3F-LXXLLsyn and pCoAT7H3F-RS constructs with all of the clones 
analysed, other constructs produced various products and only few of the clones produced the 
correct PCR product. For the constructs, where colony PCR produced only correct product 
with all of the clones, it may be that the ligation was more efficient than for the constructs 
where only few clones produced the correct product. The regions of the vector, where 
unspecific primer annealing occurred may have been also could be amplified. In this case, the 
colony did not contain the correct insert and the PCR reaction may have been shifted towards 
unspecific amplification. 
 
In further analysis, restriction endonucleases were used to verify the constructs and the size of 
the inserts. The restriction enzymes were selected either to cut out the insert using the cloning 
 59 
sites or to digest inside the insert and insert flanking region of the vector in order to create 
fragments that are well detectable in the gel electrophoresis. The correct digestion profiles 
were obtained from every construct except the LXXLLsyn. However, there seemed to be a 
problem with XbaI digestion, because it failed to cut any of the LXXLLsyn constructs or the 
empty pCoAT7H3F vector. Since by codon-optimization procedure all the intrinsic sites were 
removed from this insert, it was difficult to find restriction enzymes adequate for the 
successful analysis. Despite the lack of the restriction analysis, hCAR LBD was sub-cloned 
into the pCoAT7H3F-LXXLLsyn construct. The colony PCR and restriction analysis for the 
CAR-LXXLLsyn construct showed that the construct was correct. 
 
Sequencing was performed with the 3xFLAG or HAT primers from 5’ prime and with T7 
terminator primer from 3’ prime. The T7 primer was added by the sequencing facility. 
However, none of the T7 terminator sequencing samples resulted any readable sequence. The 
3xFLAG and HAT primers were working and the sequencing results confirmed that every 
construct except the full-length hPGC1 alone or in combination with hCAR were correct. 
Although the pCoAT7H3F-CAR-PGC1-FL contained hCAR but the full-length hPGC1 
was absent. 
 
6.4 Mini scale protein expression tests 
 
The mini scale expression was analyzed by SDS-PAGE with Coomassie Blue staining for RS 
and LXXLLsyn domains and possibly hCAR. The expression levels of the proteins in E. coli 
were small for all proteins except the LXXLLsyn domain. In addition, 3xFLAG-hRXRα in 
the same co-expression vector was taken as a positive control for the expression. The 
expression of LXXLLsyn and hRXRα showed that the 3xFLAG fusion in the co-expression 
vector was functional. However, there was no clear co-expression of hCAR with any of the 
3xFLAG-tagged proteins. This could be due to that the E. coli could not process the 
expression from two T7 initiator sites or the equilibrium was shifted to expressing only the 
one of the two proteins. 
 
The expression level for the LXXLLsyn was higher compared to LXXLL or RS domains. 
This could indicate that the codon optimization for the synthesized LXXLL gene aided the 
expression process in E. coli. However, the wild-type LXXLL and LXXLLsyn do not have 
the same size thus the direct comparison of the expression between these two constructs is 
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difficult. hPGC1α contains rare codons for E. coli and this could decrease the protein 
expression level. A rare codon analysis for 3xFLAG-LXXLL and 3xFLAG-RS was 
performed using online tool at Genscript website (http://www.genscript.com/cgi-
bin/tools/rare_codon_analysis). The results showed that both recombinant proteins are not 
optimal for expression in E. coli host. The Codon Adaption Index (CAI) indicates the 
frequency of codons used in translation from mRNA to protein with CAI of 1.0 being the 
ideal expression level and >0.8 is considered as good for expression. 3xFLAG-LXXLL 
resulted in CAI of 0.59 and 3xFLAG-RS in 0.61. The protein expression was tested with 
different E. coli strains and one was BL21(DE3) with pRARE plasmid. pRARE contains 
genes for tRNAs with codons rare for E. coli and therefore should enhance protein expression 
(Novy et al. 2001). In addition, the prediction of protein disorder for hPGC1α using 
DISOPRED version 2 server (http://bioinf.cs.ucl.ac.uk/disopred/) indicated that in most of the 
protein sequence hPGC1α is an intrinsically disordered protein This further hinder its 
expression in E. coli and the sub-optimal solution is to use folded domain parts with co-
expression of the partner proteins. Moreover, there is a possibility to shift to different host 
such as yeast or insect cells that may provide better result in terms of protein quality and 
yield. 
 
The calculated protein size for HAT-hCAR is approximately 32 kDa. In the protein 
expression test, hCAR was visible around 30 kDa in the 12 % SDS-PAGE. The calculated 
protein size for 3xFLAG-LXXLLsyn is approximately 21 kDa, but it seemed to migrate 
around 25 kDa. The small difference between the sizes of the two proteins caused difficulties 
in their detection from the hCAR and LXXLLsyn co-expression tests. The hCAR-LXXLLsyn 
co-expression sample was separated with 16 % SDS-PAGE and ran for 75 and 105 min in 
order to detect the two proteins (data not shown). However, there seemed to be only one band 
around 25 kDa. Therefore it can be suspected that there is only LXXLLsyn expressed. 
 
6.5 Western blot 
 
The Coomassie Blue staining was possibly not sensitive enough to detect the low levels of 
protein expression and therefore Western blot was performed. Western blotting was also 
performed in order to verify the protein sizes of 3xFLAG- and HAT-tagged proteins using 
antibodies against FLAG and 6xHis. HAT tag is bigger and largely differs from the 6xHis tag 
and therefore it was expected that the antibody may not work for the HAT fusion proteins. As 
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expected, there were no visible bands after the 700 nm scan. However, the 6xHis antibody 
seemed not to be able to detect the 6xHis-VDR in any of the experiments that has been 
visualized with Coomassie Blue staining. However, there is no certainty of why 6xHis-VDR 
was not visible and better positive controls are needed in future experiments. Western blot 
was performed for crude lysate and supernatant samples. 
 
The FLAG antibody seemed to bind unspecifically to various proteins blotted to the 
membranes and therefore the detection of the 3xFLAG-tagged LXXLL and RS domains was 
difficult. The 3xFLAG-hRXRα was clearly visible in both crude lysate and supernatant 
samples due to its high expression, which was also visible with Coomassie Blue staining. In 
addition, the LXXLLsyn was visible with Coomassie Blue staining and could therefore be 
distinguished. The detection of hRXRα and LXXLLsyn showed that the Western blot was 
successful and the FLAG antibody was binding to the 3xFLAG fusion proteins, despite the 
unspecific binding. The unspecific binding could have been reduced by testing different 
blocking solutions, for example the Odyssey blocking buffer recommended by the LI-COR 
company, or using more pure protein samples. 
 
Using the crude lysate samples, RS was detected with western blot and Coomassie Blue 
staining and hCAR from hCAR-RS was also visible with Coomassie staining. LXXLL was 
difficult to detect from Western blot membrane due to many unspecific bands. Moreover, 
LXXLL was not visible with Coomassie Blue staining. However, there seemed to be a band 
around 60 kDa in the LXXLL and hCAR-LXXLL samples that was detected from the 
Western blot membrane using crude lysate and supernatant samples. Therefore, there is an 
indication of protein expression of every recombinant protein used in this study. 
 
6.6 Co-purification of hCAR and hPGC1 domains 
 
Protein purification was performed using metal affinity beads binding to the HAT tag. The 
main aim was to co-purify hPGC1 domain proteins with HAT-tagged hCAR. This would 
indicate the interactions between hCAR and hPGC1 LXXL and RS domains.  
 
The results from protein purifications showed that hCAR was purified from all of the 
samples. However, LXXLL, RS and LXXLLsyn were not clearly visible from the purified 
 62 
samples. This could be due to the very low level of protein expression and thus not enough 
LXXLL or RS to interact with hCAR. However, in the co-purification with LXXLLsyn an 
approximately 55 kDa band appeared which was not visible in other protein purifications. 
One option could be that the transcription of the mRNA did not stop after hCAR and 
continued to the end of LXXLLsyn. This would result in a protein of approximately 55 kDa. 
However, this is highly unlikely due to the presence of astop-codon at the end of hCAR and 
there a hCAR with the correct size expressed at high level. 
 
Performing the co-purification of hCAR and hPGC1α domains in larger culture volumes 
could have yielded more hPGC1α and the interaction could have been detected better. There 
was a band around 40 kDa in co-purification of RS with hCAR (Figure 17, lane 13), which 
was not clearly visible in the co-purifications for other proteins. The calculated size for RS 
domain is 39 kDa and therefore it could be that the RS domain was co-purified with hCAR. 
Shiraki and colleagues (Shiraki et al. 2003) showed that also RS domain has the ability to 
bind directly to hCAR LBD, despite the fact that LXXLL motif is important region for the 
activation of NRs (Savkur & Burris 2004). The hCAR-LXXLL co-expression plasmid yielded 
only low level of proteins and this could affect that the binding of LXXLL to hCAR was not 
detected. However, the LXXLLsyn was expressed in higher level, but due to the close 
proximity of the LXXLLsyn and the hCAR LBD, the LXXLLsyn was overlaid by hCAR. 
 
6.7 Cell culturing and reporter gene assays 
 
Cell culturing was performed with MCF-7 cell line, because it is a common, easy to use cell 
line that is widely used for reporter gene assays. Titration of hCAR with pGL3-PBREM using 
two different DNA-PEI ratios, 1:1 and 1:2, showed that 1:1 ratio and lower hCAR amounts 
resulted in higher luciferase activity. It has been observed that cell-type specific high DNA 
doses may create atypical signaling in cells such as quenching of cofactors leading to artifacts. 
This could be one of the reasons, why high DNA levels of hCAR would not produce higher 
activities. Therefore 50 and 100 ng of hCAR were tested in further hPGC1 titration. 
 
The results showed that hPGC1 failed to further increase the activity of hCAR and 
eventually a dose dependent decrease in the hCAR’s activity was observed compared to 
samples with absent hPGC1. This could be due to the fact that MCF-7 cells contain high 
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levels of intrinsic coactivators and this may have interfered with hCAR-hPGC1 interaction. 
For example signaling pathways of the p160 coactivator family have been shown to have a 
key role in breast cancer cells (Wertheimer et al. 2012). Moreover, RAC3 coactivator has 
been shown to interact with hCAR in a ligand-independent manner (Molnár et al. 2005). This 
could be one factor interfering with the hPGC1 mediated activation of hCAR. Therefore 
C3A cell line was also tested. C3A cells are hepatocytes and therefore ideal to use for hCAR 
studies, because hCAR is primarily expressed in the liver in vivo. 
 
Results from the reporter gene assays using C3A cells differed from using the MCF-7 cells. 
The titration of hCAR showed that much higher amount, 500 ng, seemed to be the optimal 
and DNA-PEI ratio of 1:1 yielded higher activities that 1:2, which was same as with MCF-7. 
The titration of hPGC1 resulted in only 1.5-fold increase in the activation of hCAR and no 
dose dependent response was detected. The different amounts of hPGC1 did not shown any 
specific trends. The highest activities were in samples with 100 and 1000 ng and the lowest 
activities with 50 and 250 ng of PGC1. 
 
However, the response element, PBREM, was not optimized and this could have affected the 
results. Therefore, the titration of hPGC1 using C3A cells was repeated with 100 ng of 
PBREM. Interestingly, the profile of the titration changed and dose response dependence was 
detected. The increase of PGC1 increased the activity and 1000 ng of PGC1 resulted in the 
highest activity with 5.7-fold increase compared to PBREM with 500 ng of hCAR. It seems 
that the amount of the total DNA and the ratio for different plasmids are important in order to 
obtain reliable results. It would be beneficial to optimize the amount of every plasmid used in 
the assay and use the optimal ratio of DNA and transformation reagent. 
 
7 CONCLUSIONS AND FUTURE DIRECTIONS 
 
The aim of this thesis was to investigate the protein-protein interaction of recombinant nuclear 
receptor hCAR and coactivator hPGC1α using the prepared tools. The large part of this 
project was the preparation of various expression and co-expression constructs to produce 
recombinant hCAR and hPGC1α. The reporter gene assays using full-length hCAR and 
hPGC1α showed that hPGC1α activates hCAR with maximum of 5.7-fold. The next step will 
be the testing of different ligands in order to determine the possibility of the ligand-dependent 
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mediation of the protein-protein interaction. The interactions may be investigated using 
mammalian two-hybrid assay with just LBD domain of hCAR and different fragments of 
hPGC1α. In a longer time scale this may result in finding novel therapeutical compounds for 
treatment of various diseases such as diabetes or cardiovascular disease. 
 
The detailed investigation for the impact of hCAR-hPGC1α interaction of different regions of 
hPGC1α was incomplete due to lack of time. However, there was some indication for 
interaction of the RS domain with hCAR LBD in the co-purification assays. The expressions 
and purifications will be done using larger cultures in order to gain more proteins. In addition, 
the purification will be done for the constructs with hPGC1α domains in the absence of hCAR 
and comparing these purification profiles with the co-purification profiles of LXXLL and RS 
domains in the presence of hCAR could high-light the hPGC1α domains in the SDS-PAGE 
analysis. The interesting triple band around 25 to 30 kDa in the purifications of hCAR without 
and with hPGC1α proteins will be studied using mass spectrometry. This may reveal whether 
the bands are fragments of hCAR. Mass spectrometry will be used to investigate the 55 kDa 
band in hCAR-LXXLLsyn purification, whether it contains the LXXLLsyn or hCAR. 
 
The proteins will be purified in large quantities and will be used in interaction studies for 
example limited protease digestion, which may give more specific information about the 
stability of the protein complex. In addition, AlphaScreen will be used to investigate the 
binding affinities between hCAR and full-length or different motifs of PGC1α. These assays 
will be performed in the presence of ligands, which may show their effect on the stability of 
the interaction. 
 
This study describes the preparation of the tools and optimization of the methods needed for 
the protein-protein interaction studies using hCAR and hPGC1α. Preliminary results show 
that there is interaction between these two proteins that involves both LXXLL and RS 
domains. The aim of the further studies may be to identify the specific regions important for 
this interaction. 
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APPENDIX A 
Maps of the recombinant co-expression vectors 
 
Abbreviations 
Ap ampicillin resistance gene 
3C PCS 3C protease cleavage site 
TEV PCS TEV protease cleavage site 
lacI lac repressor gene 
lacO lac operon 
RBS ribosome binding site 
f1 origin of replication 
ROP repressor of primer 
ColE1, pB322 ori origin of replication 
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APPENDIX B 
Alignment query for human full-length PGC1α (query) and mouse full-length PGC1α 
(subject) nucleic acid sequences 
 
LLAVL motif (262-276), LKKLL motif (430-444), LLKYL motif (628-642), interaction with 
PPAR (877-1017), RS domain (1696-1797), RS motif (1861-1900) and RRM motif (2029-
2259) highlighted in grey with differences highlighted in red. 
 
>lcl|10717 gi|238018130:140-2533 Mus musculus peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha (Ppargc1a), transcript variant 1, mRNA 
 
Length=2394 
Score = 3175 bits (1719), Expect = 0.0 
Identities = 2087/2267 (92%), Gaps = 15/2267 (1%) 
Strand=Plus/Plus 
 
Query  140   ATACAGACAGCTTTCTGGGTGGACTCAAGTGGTGCAGTGACCAATCAGAAATAATATCCA  199 
             ||||||||||||||||||||||| | |||||||| || |||||||| ||||| ||||||| 
Sbjct  134   ATACAGACAGCTTTCTGGGTGGATTGAAGTGGTGTAGCGACCAATCGGAAATCATATCCA  193 
 
Query  200   ATCAGTACAACAATGAGCCTTCAAACATATTTGAGAAGATAGATGAAGAGAATGAGGCAA  259 
             | |||||||||||||||||| | ||||||||||||||||||||||||||||||||||||| 
Sbjct  194   ACCAGTACAACAATGAGCCTGCGAACATATTTGAGAAGATAGATGAAGAGAATGAGGCAA  253 
 
Query  260   ACTTGCTAGCAGTCCTCACAGAGACACTAGACAGTCTCCCTGTGGATGAAGACGGATTGC  319 
             |||||||||| || |||||||||||||| ||||||||||| ||||||||||||||||||| 
Sbjct  254   ACTTGCTAGCGGTTCTCACAGAGACACTGGACAGTCTCCCCGTGGATGAAGACGGATTGC  313 
 
Query  320   CCTCATTTGATGCGCTGACAGATGGAGACGTGACCACTGACAATGAGGCTAGTCCTTCCT  379 
             ||||||||||||| ||||||||||||| ||||||||||||||| ||||| |||||||||| 
Sbjct  314   CCTCATTTGATGCACTGACAGATGGAGCCGTGACCACTGACAACGAGGCCAGTCCTTCCT  373 
 
Query  380   CCATGCCTGACGGCACCCCTCCACCC-CAGGAGGCAGAAGAGCCGTCTCTACTTAAGAAG  438 
             |||||||||||||||||||||| ||| ||||||||||||||||||||||||||||||||| 
Sbjct  374   CCATGCCTGACGGCACCCCTCC-CCCTCAGGAGGCAGAAGAGCCGTCTCTACTTAAGAAG  432 
 
Query  439   CTCTTACTGGCACCAGCCAACACTCAGCTAAGTTATAATGAATGCAGTGGTCTCAGTACC  498 
             ||||||||||||||||||||||||||||| || || ||||||||||| ||||| || ||  
Sbjct  433   CTCTTACTGGCACCAGCCAACACTCAGCTCAGCTACAATGAATGCAGCGGTCTTAGCACT  492 
 
Query  499   CAGAACCAT---GCAAATCACAATCACAGGATCAGAACAAACCCTGCAATTGTTAAGACT  555 
             |||||||||   ||||| ||||  ||||||||||||||||||||||| |||||||||||  
Sbjct  493   CAGAACCATGCAGCAAACCACACCCACAGGATCAGAACAAACCCTGCCATTGTTAAGACC  552 
 
Query  556   GAGAATTCATGGAGCAATAAAGCGAAGAGTATTTGTCAACAGCAAAAGCCACAAAGACGT  615 
             ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
Sbjct  553   GAGAATTCATGGAGCAATAAAGCGAAGAGCATTTGTCAACAGCAAAAGCCACAAAGACGT  612 
 
Query  616   CCCTGCTCGGAGCTTCTCAAATATCTGACCACAAACGATGACCCTCCTCACACCAAACCC  675 
             |||||||| ||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  613   CCCTGCTCAGAGCTTCTCAAGTATCTGACCACAAACGATGACCCTCCTCACACCAAACCC  672 
 
Query  676   ACAGAGAACAGAAACAGCAGCAGAGACAAATGCACCTCCAAAAAGAAGTCCCACACACAG  735 
             ||||| ||||| ||||||||||||||||||||  | || |||||||||||||| |||||  
Sbjct  673   ACAGAAAACAGGAACAGCAGCAGAGACAAATGTGCTTCGAAAAAGAAGTCCCATACACAA  732 
 
Query  736   TCGCAGTCACAACACT--TACAAGCCAAACCAACAACTTTATCTCTTCCTCTGACCCCAG  793 
              ||||||| ||||| |  | |||||||||||||||||||||||||||||||||||||||| 
Sbjct  733   CCGCAGTCGCAACA-TGCT-CAAGCCAAACCAACAACTTTATCTCTTCCTCTGACCCCAG  790 
 
Query  794   AGTCACCAAATGACCCCAAGGGTTCCCCATTTGAGAACAAGACTATTGAACGCACCTTAA  853 
             ||||||||||||||||||||||||||||||||||||||||||||||||| || ||||||| 
Sbjct  791   AGTCACCAAATGACCCCAAGGGTTCCCCATTTGAGAACAAGACTATTGAGCGAACCTTAA  850 
 
Query  854   GTGTGGAACTCTCTGGAACTGCAGGCCTAACTCCACCCACCACTCCTCCTCATAAAGCCA  913 
             |||||||||||||||||||||||||||||||||| ||||| ||||||||||||||||||| 
Sbjct  851   GTGTGGAACTCTCTGGAACTGCAGGCCTAACTCCTCCCACAACTCCTCCTCATAAAGCCA  910 
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Query  914   ACCAAGATAACCCTTTTAGGGCTTCTCCAAAGCTGAAGTCCTCTTGCAAGACTGTGGTGC  973 
             |||||||||||||||| | |||||| |||||||||||| ||||||||||||| ||||||| 
Sbjct  911   ACCAAGATAACCCTTTCAAGGCTTCGCCAAAGCTGAAGCCCTCTTGCAAGACCGTGGTGC  970 
 
Query  974   CACCACCATCAAAGAAG-CCCAGGTACAGTGAGTCTTCTGGTACACAAGGCAATAACTCC  1032 
             |||| ||| | |||| | ||| |||||||||||| ||||||||| |||||||   ||||| 
Sbjct  971   CACCGCCAACCAAGAGGGCCC-GGTACAGTGAGTGTTCTGGTACCCAAGGCAGCCACTCC  1029 
 
Query  1033  ACCAAGAAAGGGCCGGAGCAATCCGAGTTGTATGCACAACTCAGCAAGTCCTCAGTCCTC  1092 
             |||||||||||||| |||||||| |||||||| ||||||||||||||||||||||  ||| 
Sbjct  1030  ACCAAGAAAGGGCCCGAGCAATCTGAGTTGTACGCACAACTCAGCAAGTCCTCAGGGCTC  1089 
 
Query  1093  A-CTGGTGGACACGAGGAAAGGAAGACCAAGCGGCCCAGTCTGCGGCTGTTTGGTGACCA  1151 
             | | |  |||||||||||||||||||| || ||||||||||| ||||||||||||||||| 
Sbjct  1090  AGCCGA-GGACACGAGGAAAGGAAGACTAAACGGCCCAGTCTCCGGCTGTTTGGTGACCA  1148 
 
Query  1152  TGACTATTGCCAGTCAATTAATTCCAAAACAGAAATACTCATTAATATATCACAGGAGCT  1211 
             |||||| || |||||| | ||||||||||| || ||||||||||| |||||||||||||| 
Sbjct  1149  TGACTACTGTCAGTCACTCAATTCCAAAACGGATATACTCATTAACATATCACAGGAGCT  1208 
 
Query  1212  CCAAGACTCTAGACAACTAGAAAAT-AAAGATGTCTCCTCTGATTGGCAGGGGCAGATTT  1270 
             |||||||||||||||||||||   | ||||||| ||||| ||| ||||||||||| || | 
Sbjct  1209  CCAAGACTCTAGACAACTAGACT-TCAAAGATGCCTCCTGTGACTGGCAGGGGCACATCT  1267 
 
Query  1271  GTTCTTCCACAGATTCAGACCAGTGCTACCTGAGAGAGACTTTGGAGGCAAGCAAGCAGG  1330 
             |||||||||||||||||| |||||||||||||||||||||||||||||| |||||||||| 
Sbjct  1268  GTTCTTCCACAGATTCAGGCCAGTGCTACCTGAGAGAGACTTTGGAGGCCAGCAAGCAGG  1327 
 
Query  1331  TCTCTCCTTGCAGCACAAGAAAACAGCTCCAAGACCAGGAAATCCGAGCCGAGCTGAACA  1390 
             |||||||||||||||| |||||||||||||||||||||||||||||||| |||||||||| 
Sbjct  1328  TCTCTCCTTGCAGCACCAGAAAACAGCTCCAAGACCAGGAAATCCGAGCGGAGCTGAACA  1387 
 
Query  1391  AGCACTTCGGTCATCCCAGTCAAGCTGTTTTTGACGACGAAGCAGACAAGACCGGTGAAC  1450 
             ||||||||||||||||| |||||||||| ||||||||| || ||||||||||| |||||| 
Sbjct  1388  AGCACTTCGGTCATCCCTGTCAAGCTGTGTTTGACGACAAATCAGACAAGACCAGTGAAC  1447 
 
Query  1451  TGAGGGACAGTGATTTCAGTAATGAACAATTCTCCAAACTACCTATGTTTATAAATTCAG  1510 
             | |||||  | || |||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct  1448  TAAGGGATGGCGACTTCAGTAATGAACAATTCTCCAAACTACCTGTGTTTATAAATTCAG  1507 
 
Query  1511  GACTAGCCATGGATGGCCTGTTTGATGACAGCGAAGATGAAAGTGATAAACTGAGCTACC  1570 
             ||||||||||||||||||| ||||||||||| |||||||||||||||||||||||||||| 
Sbjct  1508  GACTAGCCATGGATGGCCTATTTGATGACAGTGAAGATGAAAGTGATAAACTGAGCTACC  1567 
 
Query  1571  CTTGGGATGGCACGCAATCCTATTCATTGTTCAATGTGTCTCCTTCTTGTTCTTCTTTTA  1630 
             ||||||||||||||||  |||||||||||||| ||||||| |||||||| ||||| |||| 
Sbjct  1568  CTTGGGATGGCACGCAGCCCTATTCATTGTTCGATGTGTCGCCTTCTTGCTCTTCCTTTA  1627 
 
Query  1631  ACTCTCCATGTAGAGATTCTGTGTCACCACCCAAATCCTTATTTTCTCAAAGACCCCAAA  1690 
             ||||||| ||| |||| || ||||||||||| |||||||||||||||||||||||||||| 
Sbjct  1628  ACTCTCCGTGTCGAGACTCAGTGTCACCACCGAAATCCTTATTTTCTCAAAGACCCCAAA  1687 
 
Query  1691  GGATGCGCTCTCGTTCAAGGTCCTTTTCTCGACACAGGTCGTGTTCCCGATCACCATATT  1750 
             ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  1688  GGATGCGCTCTCGTTCAAGATCCTTTTCTCGACACAGGTCGTGTTCCCGATCACCATATT  1747 
 
Query  1751  CCAGGTCAAGATCAAGGTCTCCAGGCAGTAGATCCTCTTCAAGATCCTGCTATTACTATG  1810 
             ||||||||||||||||||| ||||||||||||||||||||||||||||| || ||||||| 
Sbjct  1748  CCAGGTCAAGATCAAGGTCCCCAGGCAGTAGATCCTCTTCAAGATCCTGTTACTACTATG  1807 
 
Query  1811  AGTCAAGCCACTACAGACACCGCACGCACCGAAATTCTCCCTTGTATGTGAGATCACGTT  1870 
             | ||||||||||||||||||||||| ||||| |||||||||||||||||||||||||||| 
Sbjct  1808  AATCAAGCCACTACAGACACCGCACACACCGCAATTCTCCCTTGTATGTGAGATCACGTT  1867 
 
Query  1871  CAAGATCGCCCTACAGCCGTCGGCCCAGGTATGACAGCTACGAGGAATATCAGCACGAGA  1930 
             |||| || |||||||||||| |||||||||| |||||||| || |  ||| ||||||| | 
Sbjct  1868  CAAGGTCACCCTACAGCCGTAGGCCCAGGTACGACAGCTATGAAGCCTATGAGCACGAAA  1927 
 
Query  1931  GGCTGAAGAGGGAAGAATATCGCAGAGAGTATGAGAAGCGAGAGTCTGAGAGGGCCAAGC  1990 
             |||| |||||||| ||||| |||| |||| | |||||||| |||||||| |||||||| | 
Sbjct  1928  GGCTCAAGAGGGATGAATACCGCAAAGAGCACGAGAAGCGGGAGTCTGAAAGGGCCAAAC  1987 
 
Query  1991  AAAGGGAGAGGCAGAGGCAGAAGGCAATTGAAGAGCGCCGTGTGATTTATGTCGGTAAAA  2050 
             | || |||||||||| |||||| |||||||||||||||||||||||||| || ||||||| 
Sbjct  1988  AGAGAGAGAGGCAGAAGCAGAAAGCAATTGAAGAGCGCCGTGTGATTTACGTTGGTAAAA  2047 
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Query  2051  TCAGACCTGACACAACACGGACAGAACTGAGGGACCGTTTTGAAGTTTTTGGTGAAATTG  2110 
             |||||||||||||||| ||||||||| |||| ||||| |||||||||||||||||||||| 
Sbjct  2048  TCAGACCTGACACAACGCGGACAGAATTGAGAGACCGCTTTGAAGTTTTTGGTGAAATTG  2107 
 
Query  2111  AGGAGTGCACAGTAAATCTGCGGGATGATGGAGACAGCTATGGTTTCATTACCTACCGTT  2170 
             |||| ||||| |||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct  2108  AGGAATGCACCGTAAATCTGCGGGATGATGGAGACAGCTATGGTTTCATCACCTACCGTT  2167 
 
Query  2171  ATACCTGTGATGCTTTTGCTGCTCTTGAAAATGGATACACTTTGCGCAGGTCAAACGAAA  2230 
             | |||||||| ||||| ||||||||||| |||||||| ||||| |||||||| ||||||| 
Sbjct  2168  ACACCTGTGACGCTTTCGCTGCTCTTGAGAATGGATATACTTTACGCAGGTCGAACGAAA  2227 
 
Query  2231  CTGACTTTGAGCTGTACTTTTGTGGACGCAAGCAATTTTTCAAGTCTAACTATGCAGACC  2290 
             ||||||| |||||||||||||||||||| ||||||||||||||||||||||||||||||| 
Sbjct  2228  CTGACTTCGAGCTGTACTTTTGTGGACGGAAGCAATTTTTCAAGTCTAACTATGCAGACC  2287 
 
Query  2291  TAGATTCAAACTCAGATGACTTTGACCCTGCTTCCACCAAGAGCAAGTATGACTCTCTGG  2350 
             ||||| | |||||||| || |||||||||||||||||||||||||||||||||||||||| 
Sbjct  2288  TAGATACCAACTCAGACGATTTTGACCCTGCTTCCACCAAGAGCAAGTATGACTCTCTGG  2347 
 
Query  2351  ATTTTGATAGTTTACTGAAAGAAGCTCAGAGAAGCTTGCGCAGGTAA  2397 
             ||||||||||||||||||| ||||||||||||||||||||||||||| 
Sbjct  2348  ATTTTGATAGTTTACTGAAGGAAGCTCAGAGAAGCTTGCGCAGGTAA  2394 
 
Alignment query for human full-length PGC1α (query) and mouse full-length PGC1α 
(subject) amino acid sequences 
 
LLAVL motif (88-92), LKKLL motif (144-148), LLKYL motif (210-214), interaction with 
PPAR (293-338), RS domain (566-599), RS motif (621-634) and RRM (677-754) motif 
highlighted in grey and differences in red. 
 
>lcl|6151 unnamed protein product 
Length=797 
 
 Score = 1402 bits (3628),  Expect = 0.0, Method: Compositional matrix adjust. 
 Identities = 755/799 (94%), Positives = 776/799 (97%), Gaps = 3/799 (0%) 
 
Query  1    MAWDMCNQDSESVWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSD  60 
            MAWDMC+QDS  VWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSD 
Sbjct  1    MAWDMCSQDS--VWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSD  58 
 
Query  61   QSEIISNQYNNEPSNIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGDVTTD  120 
            QSEIISNQYNNEP+NIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDG VTTD 
Sbjct  59   QSEIISNQYNNEPANIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGAVTTD  118 
 
Query  121  NEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHA-NHNHRIRTN  179 
            NEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHA NH HRIRTN 
Sbjct  119  NEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHAANHTHRIRTN  178 
 
Query  180  PAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKCTSK  239 
            PAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKC SK 
Sbjct  179  PAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKCASK  238 
 
Query  240  KKSHTQSQSQHLQAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTT  299 
            KKSHTQ QSQH QAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTT 
Sbjct  239  KKSHTQPQSQHAQAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTT  298 
 
Query  300  PPHKANQDNPFRASPKLKSSCKTVVPPPSKKPRYSESSGTQGNNSTKKGPEQSELYAQLS  359 
            PPHKANQDNPF+ASPKLK SCKTVVPPP+K+ RYSE SGTQG++STKKGPEQSELYAQLS 
Sbjct  299  PPHKANQDNPFKASPKLKPSCKTVVPPPTKRARYSECSGTQGSHSTKKGPEQSELYAQLS  358 
 
Query  360  KSSVLTGGHEERKTKRPSLRLFGDHDYCQSINSKTEILINISQELQDSRQLENKDVSSDW  419 
            KSS L+ GHEERKTKRPSLRLFGDHDYCQS+NSKT+ILINISQELQDSRQL+ KD S DW 
Sbjct  359  KSSGLSRGHEERKTKRPSLRLFGDHDYCQSLNSKTDILINISQELQDSRQLDFKDASCDW  418 
 
Query  420  QGQICSSTDSDQCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHPSQAVFDDEAD  479 
            QG ICSSTDS QCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHP QAVFDD++D 
Sbjct  419  QGHICSSTDSGQCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHPCQAVFDDKSD  478 
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Query  480  KTGELRDSDFSNEQFSKLPMFINSGLAMDGLFDDSEDESDKLSYPWDGTQSYSLFNVSPS  539 
            KT ELRD DFSNEQFSKLP+FINSGLAMDGLFDDSEDESDKLSYPWDGTQ YSLF+VSPS 
Sbjct  479  KTSELRDGDFSNEQFSKLPVFINSGLAMDGLFDDSEDESDKLSYPWDGTQPYSLFDVSPS  538 
 
Query  540  CSSFNSPCRDSVSPPKSLFSQRPQRMRSRSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRS  599 
            CSSFNSPCRDSVSPPKSLFSQRPQRMRSRSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRS 
Sbjct  539  CSSFNSPCRDSVSPPKSLFSQRPQRMRSRSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRS  598 
 
Query  600  CYYYESSHYRHRTHRNSPLYVRSRSRSPYSRRPRYDSYEEYQHERLKREEYRREYEKRES  659 
            CYYYESSHYRHRTHRNSPLYVRSRSRSPYSRRPRYDSYE Y+HERLKR+EYR+E+EKRES 
Sbjct  599  CYYYESSHYRHRTHRNSPLYVRSRSRSPYSRRPRYDSYEAYEHERLKRDEYRKEHEKRES  658 
 
Query  660  ERAKQRERQRQKAIEERRVIYVGKIRPDTTRTELRDRFEVFGEIEECTVNLRDDGDSYGF  719 
            ERAKQRERQ+QKAIEERRVIYVGKIRPDTTRTELRDRFEVFGEIEECTVNLRDDGDSYGF 
Sbjct  659  ERAKQRERQKQKAIEERRVIYVGKIRPDTTRTELRDRFEVFGEIEECTVNLRDDGDSYGF  718 
 
Query  720  ITYRYTCDAFAALENGYTLRRSNETDFELYFCGRKQFFKSNYADLDSNSDDFDPASTKSK  779 
            ITYRYTCDAFAALENGYTLRRSNETDFELYFCGRKQFFKSNYADLD+NSDDFDPASTKSK 
Sbjct  719  ITYRYTCDAFAALENGYTLRRSNETDFELYFCGRKQFFKSNYADLDTNSDDFDPASTKSK  778 
 
Query  780  YDSLDFDSLLKEAQRSLRR  798 
            YDSLDFDSLLKEAQRSLRR 
Sbjct  779  YDSLDFDSLLKEAQRSLRR  797 
 
Alignment query for human PGC1α-LXXLL (query) and mouse PGC1α-LXXLL 
(subject) amino acid sequences 
 
LLAVL motif (88-92), LKKLL motif (144-148), LLKYL motif (210-214) and interaction 
with PPAR (293-338) highlighted in grey and differences in red. 
 
>lcl|61693 unnamed protein product 
 
Length=506 
Score =  946 bits (2444), Expect = 0.0, Method: Compositional matrix adjust.  
Identities = 473/508 (93%), Positives = 487/508 (96%), Gaps = 3/508 (1%) 
 
Query  1    MAWDMCNQDSESVWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSD  60 
            MAWDMC+QDS  VWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSD 
Sbjct  1    MAWDMCSQDS--VWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSD  58 
 
Query  61   QSEIISNQYNNEPSNIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGDVTTD  120 
            QSEIISNQYNNEP+NIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDG VTTD 
Sbjct  59   QSEIISNQYNNEPANIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGAVTTD  118 
 
Query  121  NEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHA-NHNHRIRTN  179 
            NEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHA NH HRIRTN 
Sbjct  119  NEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHAANHTHRIRTN  178 
 
Query  180  PAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKCTSK  239 
            PAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKC SK 
Sbjct  179  PAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKCASK  238 
 
Query  240  KKSHTQSQSQHLQAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTT  299 
            KKSHTQ QSQH QAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTT 
Sbjct  239  KKSHTQPQSQHAQAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTT  298 
 
Query  300  PPHKANQDNPFRASPKLKSSCKTVVPPPSKKPRYSESSGTQGNNSTKKGPEQSELYAQLS  359 
            PPHKANQDNPF+ASPKLK SCKTVVPPP+K+ RYSE SGTQG++STKKGPEQSELYAQLS 
Sbjct  299  PPHKANQDNPFKASPKLKPSCKTVVPPPTKRARYSECSGTQGSHSTKKGPEQSELYAQLS  358 
 
Query  360  KSSVLTGGHEERKTKRPSLRLFGDHDYCQSINSKTEILINISQELQDSRQLENKDVSSDW  419 
            KSS L+ GHEERKTKRPSLRLFGDHDYCQS+NSKT+ILINISQELQDSRQL+ KD S DW 
Sbjct  359  KSSGLSRGHEERKTKRPSLRLFGDHDYCQSLNSKTDILINISQELQDSRQLDFKDASCDW  418 
 
Query  420  QGQICSSTDSDQCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHPSQAVFDDEAD  479 
            QG ICSSTDS QCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHP QAVFDD++D 
Sbjct  419  QGHICSSTDSGQCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHPCQAVFDDKSD  478 
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Query  480  KTGELRDSDFSNEQFSKLPMFINSGLAM  507 
            KT ELRD DFSNEQFSKLP+FINSGLAM 
Sbjct  479  KTSELRDGDFSNEQFSKLPVFINSGLAM  506 
 
Alignment query for human PGC1α-RS (query) and mouse PGC1α-RS (subject) amino 
acid sequences 
 
RS domain (60-93), RS motif (115-127) and RRM (171-247) motif highlighted in grey and 
differences highlighted in red. 
 
>lcl|34709 unnamed protein product 
 
Length=291 
Score =  442 bits (1136), Expect = 5e-129, Method: Compositional matrix adjust. 
Identities = 282/291 (97%), Positives = 289/291 (99%), Gaps = 0/291 (0%) 
 
Query  2    DGLFDDSEDESDKLSYPWDGTQSYSLFNVSPSCSSFNSPCRDSVSPPKSLFSQRPQRMRS  61 
            DGLFDDSEDESDKLSYPWDGTQ YSLF+VSPSCSSFNSPCRDSVSPPKSLFSQRPQRMRS 
Sbjct  1    DGLFDDSEDESDKLSYPWDGTQPYSLFDVSPSCSSFNSPCRDSVSPPKSLFSQRPQRMRS  60 
 
Query  62   RSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRSCYYYESSHYRHRTHRNSPLYVRSRSRSP  121 
            RSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRSCYYYESSHYRHRTHRNSPLYVRSRSRSP 
Sbjct  61   RSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRSCYYYESSHYRHRTHRNSPLYVRSRSRSP  120 
 
Query  122  YSRRPRYDSYEEYQHERLKREEYRREYEKRESERAKQRERQRQKAIEERRVIYVGKIRPD  181 
            YSRRPRYDSYE Y+HERLKR+EYR+E+EKRESERAKQRERQ+QKAIEERRVIYVGKIRPD 
Sbjct  121  YSRRPRYDSYEAYEHERLKRDEYRKEHEKRESERAKQRERQKQKAIEERRVIYVGKIRPD  180 
 
Query  182  TTRTELRDRFEVFGEIEECTVNLRDDGDSYGFITYRYTCDAFAALENGYTLRRSNETDFE  241 
            TTRTELRDRFEVFGEIEECTVNLRDDGDSYGFITYRYTCDAFAALENGYTLRRSNETDFE 
Sbjct  181  TTRTELRDRFEVFGEIEECTVNLRDDGDSYGFITYRYTCDAFAALENGYTLRRSNETDFE  240 
 
Query  242  LYFCGRKQFFKSNYADLDSNSDDFDPASTKSKYDSLDFDSLLKEAQRSLRR  292 
            LYFCGRKQFFKSNYADLD+NSDDFDPASTKSKYDSLDFDSLLKEAQRSLRR 
Sbjct  241  LYFCGRKQFFKSNYADLDTNSDDFDPASTKSKYDSLDFDSLLKEAQRSLRR  291 
 
